Juniper Pharmaceuticals (JNP) 10-K 9 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 08, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Trading Symbol	JNP
Entity Registrant Name	JUNIPER PHARMACEUTICALS INC
Entity Central Index Key	821,995
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		10,975,208
Entity Public Float			$ 52,653,764

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 21,446	$ 20,994
Accounts receivable, net of allowances of $115 and $37 at December 31, 2017 and 2016, respectively	4,734	6,573
Inventories	6,326	5,621
Prepaid expenses and other current assets	3,467	1,539
Total current assets	35,973	34,727
Property and equipment, net	15,229	13,366
Intangible assets, net	744	969
Goodwill	9,123	8,342
Other assets	151	167
Total assets	61,220	57,571
Liabilities, contingently redeemable preferred stock, and stockholders’ equity
Accounts payable	4,038	3,893
Accrued expenses and other	5,615	5,271
Deferred revenue	6,141	5,624
Current portion of long-term debt	546	204
Total current liabilities	16,340	14,992
Long-term debt, net of current portion	3,253	2,203
Other non-current liabilities	115	56
Total liabilities	19,708	17,251
Commitments and contingencies (Note 8)
Contingently redeemable series C preferred stock, 0 and 0.55 shares issued and outstanding at December 31, 2017 and 2016, respectively (liquidation preference of $0 and $550 as of December 31, 2017 and 2016, respectively)		550
Stockholders’ equity:
Preferred stock, $0.01 par value; 1,000 shares authorized Series B convertible preferred stock, 0 and 0.13 shares issued and outstanding at December 31, 2017 and 2016, respectively (liquidation preference of $0 and $13 as of December 31, 2017 and 2016, respectively)
Common stock $0.01 par value; 150,000 shares authorized; 12,257 issued and 10,844 outstanding at December 31, 2017 and 2016, respectively	123	123
Additional paid-in capital	292,108	290,636
Treasury stock (at cost), 1,413 shares at December 31, 2017 and 2016, respectively	(8,601)	(8,601)
Accumulated deficit	(238,961)	(237,360)
Accumulated other comprehensive loss	(3,157)	(5,028)
Total stockholders’ equity	41,512	39,770
Total liabilities, contingently redeemable preferred stock, and Stockholders’ equity	$ 61,220	$ 57,571

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounts receivable, allowance	$ 115	$ 37
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	12,256,980	12,257,000
Common stock, shares outstanding	10,844,113	10,844,000
Purchase of treasury shares	1,413,000	1,413,000
Series C Preferred Stock [Member]
Preferred stock, shares issued	0	550
Preferred stock, shares outstanding	0	550
Preferred stock, liquidation preference, value	$ 0	$ 550
Series B Convertible Preferred Stock [Member]
Preferred stock, shares issued	0	130
Preferred stock, shares outstanding	0	130
Preferred stock, liquidation preference, value	$ 0	$ 13

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues
Product revenues	$ 32,688	$ 27,211	$ 22,891
Service revenues	17,291	13,065	11,651
Royalties		14,297	3,745
Total revenues	49,979	54,573	38,287
Cost of product revenues	19,013	15,595	13,053
Cost of service revenues	9,948	8,698	8,361
Total cost of revenues	28,961	24,293	21,414
Gross profit	21,018	30,280	16,873
Operating expenses
Sales and marketing	1,859	1,259	1,249
Research and development	6,860	9,676	7,039
General and administrative	15,385	14,066	10,458
Restructuring charge	777
Total operating expenses	24,881	25,001	18,746
(Loss) income from operations	(3,863)	5,279	(1,873)
Interest expense, net	(130)	(97)	(106)
Other income, net	1,747	860	488
(Loss) income before income taxes	(2,246)	6,042	(1,491)
Income tax (benefit) expense	(186)	91	5
Net (loss) income	(2,060)	5,951	(1,496)
Adjustments attributable to preferred stockholders	(445)	28	28
Net (loss) income available to common stockholders	$ (1,615)	$ 5,923	$ (1,524)
Basic net (loss) income per common share	$ (0.15)	$ 0.55	$ (0.14)
Diluted net (loss) income per common share	$ (0.15)	$ 0.55	$ (0.14)
Basic weighted average common shares outstanding	10,824	10,795	10,774
Diluted weighted average common shares outstanding	10,824	10,891	10,774

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (2,060)	$ 5,951	$ (1,496)
Other comprehensive loss components:
Foreign currency translation	1,871	(3,866)	(1,099)
Total other comprehensive loss	1,871	(3,866)	(1,099)
Comprehensive (loss) income	$ (189)	$ 2,085	$ (2,595)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Series C Preferred Stock [Member]	Common Stock [Member]	Capital in Excess of Par Value [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]Series C Preferred Stock [Member]	Accumulated Other Comprehensive Income [Member]
Beginning balance at Dec. 31, 2014	$ 37,325		$ 122	$ 287,660	$ (8,579)	$ (241,815)		$ (63)
Beginning balance, shares at Dec. 31, 2014			12,186,000		(1,411,000)
Options exercised and restricted shares granted	$ 60			82	$ (22)
Options exercised and restricted shares granted, shares			29,000		(2,000)
Restricted shares granted, shares	13,106
Share based compensation expense	$ 1,750			1,750
Dividends on preferred stock	(28)			(28)
Translation adjustment	(1,099)							(1,099)
Net income (loss)	(1,496)					(1,496)
Ending balance at Dec. 31, 2015	$ 36,512		$ 122	289,464	$ (8,601)	(243,311)		(1,162)
Ending balance, shares at Dec. 31, 2015			12,215,000		(1,413,000)
Restricted shares granted			$ 1	(1)
Restricted shares granted, shares	42,203		42,000
Share based compensation expense	$ 1,201			1,201
Dividends on preferred stock	(28)			(28)
Translation adjustment	(3,866)							(3,866)
Net income (loss)	5,951					5,951
Ending balance at Dec. 31, 2016	$ 39,770		$ 123	290,636	$ (8,601)	(237,360)		(5,028)
Ending balance, shares at Dec. 31, 2016			12,257,000		(1,413,000)
Restricted shares granted, shares	66,234
Share based compensation expense	$ 1,469			1,469
Modification due to Restructuring	17			17
Gain on Conversion of Series C		$ 459					$ 459
Dividends on preferred stock	(14)			(14)
Translation adjustment	1,871							1,871
Net income (loss)	(2,060)					(2,060)
Ending balance at Dec. 31, 2017	$ 41,512		$ 123	$ 292,108	$ (8,601)	$ (238,961)		$ (3,157)
Ending balance, shares at Dec. 31, 2017			12,257,000		(1,413,000)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating activities:
Net (loss) income	$ (2,060)	$ 5,951	$ (1,496)
Reconciliation of net income to net cash provided by (used in) operating activities:
Depreciation and amortization	2,253	1,899	1,911
Share-based compensation expense	1,469	1,201	1,750
Changes in operating assets and liabilities:
Accounts receivable	2,178	192	(2,499)
Inventories	(704)	(1,998)	(424)
Prepaid expenses and other current assets	(1,849)	64	259
Other non-current assets	17	18	(89)
Accounts payable	183	1,585	(925)
Accrued expenses	225	1,214	1,591
Deferred revenue	455	1,033	(1,038)
Other long-term liabilities	(40)	27	69
Net cash provided by (used in) operating activities	2,127	11,186	(891)
Investing activities:
Purchase of property and equipment	(2,840)	(3,564)	(1,708)
Net cash used in investing activities	(2,840)	(3,564)	(1,708)
Financing activities:
Proceeds from exercise of stock options			82
Proceeds from loan facility	954
Proceeds from equipment loans	1,501
Principal payments on debt	(1,402)	(226)	(238)
Payments for the purchase of treasury stock			(22)
Dividends paid	(14)	(28)	(28)
Net cash provided by (used in) financing activities	1,039	(254)	(206)
Effect of exchange rate changes on cash and cash equivalents	126	(275)	(56)
Net increase (decrease) in cash and cash equivalents	452	7,093	(2,861)
Cash and cash equivalents, beginning of period	20,994	13,901	16,762
Cash and cash equivalents, end of period	21,446	20,994	13,901
Supplemental cash flow information
Cash paid for interest	115	85	101
Cash paid for income taxes	76		2
Supplemental noncash investing
Purchases of equipment through accounts payable and accrued expenses	320	$ 460	$ 95
Series C Preferred Stock [Member]
Supplemental noncash investing
Gain on conversion of Series C Preferred Stock	$ 459

Organization

Organization	12 Months Ended
	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization	1. Organization Juniper Pharmaceuticals, Inc. (the “Company” or “Juniper”), formerly known as Columbia Laboratories, Inc., was incorporated as a Delaware corporation in December 1986. The Company is a diversified healthcare company consisting of its Crinone® (progesterone gel) (“Crinone”) franchise and its fee-for-service pharmaceutical development and manufacturing business. Its marketed product and product development programs utilize its proprietary drug delivery technologies consisting of its bioadhesive delivery system (“BDS”), a polymer designed to adhere to epithelial surfaces or mucosa and its intra-vaginal ring (“IVR”) technology. In September 2013, the Company acquired Nottingham, U.K. based Juniper Pharma Services Ltd. (“Juniper Pharma Services”) formerly known as Molecular Profiles Ltd, a pharmaceutical services company. Juniper Pharma Services provides a range of drug development and consulting services to the pharmaceutical industry and has provided Juniper with an additional revenue source and in-house expertise for internal pharmaceutical programs. At December 31, 2017, cash and cash equivalents were $21.4 million. The Company’s future funding requirements depend on a number of factors, including the rate of market acceptance of its current and future products and services and the resources the Company devotes to developing and supporting the same. The Company believes that current cash and cash equivalents, as well as cash generated from operations, will be sufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months from the date of the filing of this Form 10-K. The Company may be dependent on its ability raise additional capital to finance operations beyond March 2019 and fund research and development programs. If the Company is not able to raise additional capital on terms acceptable to it, or at all, as and when needed, it may be required to curtail its research and development programs.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries; Columbia Laboratories Bermuda Ltd., Juniper Pharmaceuticals France SARL, Juniper Pharmaceuticals UK Ltd., and Juniper Pharma Services Ltd. All significant intercompany balances and transactions have been eliminated in consolidation. Segment information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. Juniper’s Chief Executive Officer has been identified as its CODM and evaluates the company’s performance and allocates resources based upon revenue and gross profit. The Company has concluded, based upon financial information regularly provided and reviewed, that there are two operating and reporting segments; product and services. Juniper’s CODM does not review its assets, operating expenses or non-operating income and expenses by business segment. Management Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to revenue recognition, sales return reserves, allowance for doubtful accounts, inventory reserves, impairment analysis of goodwill and intangibles including their useful lives, research and development accruals, deferred tax assets, liabilities and valuation allowances, and fair value of stock options. On an ongoing basis, management evaluates its estimates. Actual results could differ from those estimates. Foreign Currency The assets and liabilities of the Company’s subsidiaries in the United Kingdom and France are translated into U.S. dollars at current exchange rates at the end of the period and revenue and expense items are translated at average rates of exchange prevailing during the period. The functional currency of these subsidiaries is considered to be the local currency for each entity and, accordingly, translation adjustments for these subsidiaries are included in accumulated other comprehensive income (loss) within stockholders’ equity. Certain intercompany and third-party foreign currency-denominated transactions generated foreign currency remeasurement losses of approximately $0.6 million, $0.2 million and $70,000 during the years ended December 31, 2017, 2016 and 2015, respectively, which are included in other expense, net in the consolidated statements of operations. Cash Equivalents The Company considers all investments purchased with an original maturity of three months or less to be cash equivalents. Fair Value of Financial Instruments The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported values. Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 820, Fair Value Measurement and Disclosures, Level 1: Quoted prices in active markets for identical assets and liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value of cash and cash equivalents are classified as Level 1 at December 31, 2017 and 2016. Some of the estimates and assumptions in the Company's goodwill impairment assessment include: the amount and timing of the projected net cash flows, the discount rate, and the tax rate. The fair value of accounts receivable and accounts payable approximate their carrying amount. The Company’s long-term debt is carried at amortized cost, which approximates fair value based on current market pricing of similar debt instruments and is categorized as a Level 2 measurement. The Company did not have transfers of financial assets between Level 1 and Level 2. Inventories Inventories are stated at the lower of cost (first-in, first-out) or market, determined on a first-in, first-out method. We monitor standard costs on a monthly basis and update them annually as necessary to reflect change in raw material costs and labor and overhead rates. Components of inventory cost include materials, labor and manufacturing overhead. Inventories consist of the following (in thousands): December 31, 2017 2016 Raw materials $ 1,921 $ 856 Work in process 3,299 3,806 Finished goods 1,106 959 Total $ 6,326 $ 5,621 We provide inventory allowances when conditions indicate that the selling price could be less than cost due to physical deterioration, usage, obsolescence, reductions in estimated future demand and reductions in selling prices. We balance the need to maintain strategic inventory levels with the risk of obsolescence due to changing technology and customer demand levels. Unfavorable changes in market conditions may result in a need for additional inventory reserves that could adversely impact our gross margins. Reserves for excess and obsolete inventory were $0.5 million and $45,000 at December 31, 2017 and 2016, respectively. During the fiscal year ended December 31, 2017, the Company recorded charges in the condensed consolidated statements of operations for excess and obsolete inventory of $0.4 million. No charges were recorded for the fiscal year ended December 31, 2016. Unfavorable changes in market conditions may result in a need for additional inventory reserves that could adversely impact the Company’s gross margins. Accounts Receivable, net of allowances Accounts receivable are reported at their outstanding unpaid principal balances reduced by allowances for doubtful accounts. The Company estimates doubtful accounts based on its historical collection experience, factors related to specific customers’ ability to pay and current economic trends. The Company writes off accounts receivable against the allowance when a balance is determined to be uncollectable. Accounts receivable allowance activity consisted of the following for the years ended December 31 (in thousands): 2017 2016 2015 Balance at beginning of year $ 37 $ 263 $ 358 Additions 78 — — Deductions — (226 ) (95 ) Balance at end of year $ 115 $ 37 $ 263 Juniper’s accounts receivable balance, net of allowance for doubtful accounts, was $4.7 million as of December 31, 2017, and $6.6 million as of December 31, 2016. Included in the accounts receivable balance at December 31, 2017 and 2016 were $3.0 million and $1.3 million of unbilled accounts receivable, respectively. Juniper’s unbilled accounts receivable is derived from services performed that have not been billed as of the balance sheet date. Property and Equipment, net Property and equipment is stated at cost less accumulated depreciation. Leasehold improvements are amortized over the lesser of the useful life or the term of the leases. Depreciation is computed on the straight-line basis over the estimated useful lives of the respective assets, as follows: Years Machinery and equipment 3-10 Furniture and fixtures 3-5 Computer equipment and software 3-5 Buildings Up to 39 Land Indefinite Costs of major additions and improvements are capitalized and expenditures for maintenance and repairs that do not extend the life of the assets are expensed. Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are eliminated from the accounts and any resultant gain or loss is credited or charged to operations. Juniper continually evaluates whether events or circumstances have occurred that indicate that the remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. Juniper evaluates the realizability of its long-lived assets based on profitability and cash flow expectations for the related asset. Any write-downs are treated as permanent reductions in the carrying amount of the assets. Based on this evaluation, Juniper believes, as of each balance sheet date presented, none of Juniper’s long-lived assets were impaired. Concentration of Risk As of December 31, 2017, the Company has one major customer. See Note 11 of the Company’s consolidated financial statements for customer and product concentrations. The Company depends on one supplier for a key excipient (ingredient) used in its products and one supplier for one of the active pharmaceutical ingredients. Goodwill Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination. The Company does not amortize its goodwill, but instead tests for impairment annually in the fourth quarter and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than its carrying value of the asset. In September 2017, the Company announced a corporate reprioritization to allow it to focus its resources on the core businesses of Crinone progesterone gel and Juniper Pharma Services. The Company considered the announcement to be a triggering event requiring a test for impairment under ASC 350, Goodwill and Other Intangibles In accordance with ASC 350, the Company uses the two-step approach for each reporting unit. The first step compares the carrying amount of the reporting unit to its estimated fair value (Step 1) utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated using a risk-adjusted discount rate. To the extent that the carrying value of the reporting unit exceeds its estimated fair value, a second step is performed, wherein the reporting unit’s carrying value is compared to the implied fair value (Step 2). To the extent that the carrying value of goodwill exceeds the implied fair value of goodwill, impairment exists and must be recognized. The Company has concluded that its business represents two reporting units for goodwill impairment testing, which are product and service. The Company’s goodwill is assigned to its service reporting unit. The Company has performed tests for impairment as of September 18, 2017, the date of the triggering event, and October 1, 2017, the date of the annual test, and has determined that goodwill is not impaired as of either date. Furthermore, the Company also concluded that no triggering events have occurred subsequent to the most recent Step 1 goodwill impairment test. Intangible Assets The Company capitalizes and includes in intangible assets the costs of trademark, developed technology and customer relationships. Intangible assets are recorded at fair value at the time of their acquisition and stated net of accumulated amortization. The Company amortizes its intangible assets that have finite lives using either the straight-line or accelerated method, based on the useful life of the asset over which it is expected to be consumed utilizing expected undiscounted future cash flows. Amortization is recorded over the estimated useful lives ranging from 3 to 7 years. The Company evaluates the realizability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, the Company estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, the Company uses market participant assumptions pursuant to ASC 820, Fair Value Measurements Income Taxes Deferred tax assets or liabilities are determined based on timing differences between when income and expense items are recognized for financial statement purposes versus when they are recognized for tax purposes, as measured by enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be settled. A valuation allowance is provided against deferred tax assets in circumstances where management believes it is more likely than not that all or a portion of the assets will not be realized. The Company has provided a full valuation allowance in the amount of $39.1 million and $59.0 million against its net domestic and foreign deferred tax assets as of December 31, 2017 and 2016, respectively. Accumulated Other Comprehensive Loss Changes to accumulated other comprehensive loss during the year ended December 31, 2017 were as follows (in thousands): Translation Adjustment Balance – December 31, 2016 $ (5,028 ) Current period other comprehensive income (1,871 ) Balance – December 31, 2017 $ (3,157 ) No reclassification from accumulated other comprehensive loss to net (loss) income occurred during the year ended December 31, 2017. Revenue Recognition Revenues include product revenues, which primarily consist of sales of Crinone to Merck KGaA, royalty revenues, which primarily consisted of royalty revenues from Allergan on sales of Crinone until the November 2016 monetization agreement, and service revenues, which primarily consist of analytical and consulting services, pharmaceutical development and clinical trial manufacturing services and other revenues. Product Revenue Revenues from the sale of products are recognized when all of the following criteria are met: persuasive evidence of a sales arrangement exists; delivery has occurred or services have been rendered; the price is fixed or determinable; and collectability is reasonably assured. Selling prices to Merck KGaA for Crinone (progesterone gel) are determined on an annual and country-by-country basis and are the greater of (i) a percentage of Merck KGaA’s net estimated selling price, or (ii) Juniper’s direct manufacturing cost plus 20% and are invoiced to Merck KGaA upon shipment. Juniper records revenue at the minimum selling price, which is Juniper’s direct manufacturing cost plus 20% at the time of shipment to Merck KGaA as that amount is considered fixed or determinable. The Company records deferred revenue related to amounts invoiced above the minimum selling price. Upon receiving sell through information from Merck KGaA on a quarterly and country-by-country basis, the Company records an adjustment to increase revenue to reflect the difference between Merck KGaA’s actual net selling price and the minimum price recorded at the time of shipment. Any difference between the amounts invoiced at Merck KGaA’s estimated net selling price and Merck KGaA’s actual net selling price are billed or credited to Merck KGaA in the quarter the product is sold through by Merck KGaA. Accordingly, product revenue in each period includes both an amount for product shipped to Merck KGaA in the current period recognized at the minimum purchase price as well as an amount for product shipped by Merck KGaA to its customers in the current period equal to the difference between Merck KGaA’s actual net selling price and the minimum purchase price. Merck KGaA is also entitled to a volume discount based on annual purchases. The Company records reserves against revenue on a quarterly basis to reflect the volume discount expected to be earned by Merck KGaA during the year. In April 2013, Juniper’s license and supply agreement with Merck KGaA for the sale of Crinone outside the United States was renewed for an additional five-year term, extending the expiration date to May 19, 2020. In January 2018, the Company announced the extension of the supply agreement for an additional 4.5-years through at least December 31, 2024. Royalty revenues, based on sales by licensees, are recorded as revenues when those sales are made by the licensees. In November 2016, the Company received a one-time payment of $11.0 million in exchange for which Allergan will no longer be required to make future royalty payments due to Juniper. Service Revenue The professional service contracts that Juniper enters into and operates under specify whether the engagement will be billed on a time-and-materials or a fixed-price basis. These engagements generally last three to six months, although some of Juniper’s engagements can be longer in duration. Juniper recognizes substantially all of the Company’s professional services revenues under written contracts when the fee is fixed or determinable, as the services are provided, and only in those situations where collection from the client is reasonably assured. In certain cases, Juniper bills clients prior to work being performed, which requires Juniper to defer revenue in accordance with U.S. GAAP. Revenues from time-and-materials service contracts are recognized as the services are performed based upon hours worked and contractually agreed-upon hourly rates, as well as indirect fees based upon hours worked. Service revenues from a majority of Juniper’s fixed-price engagements are recognized on a proportional performance method based on the ratio of costs incurred, substantially all of which are labor-related, to the total estimated project costs. Project costs are classified in costs of services and are based on the direct salary of the employees on the engagement plus all direct expenses incurred to complete the engagement, including any amounts billed to Juniper by its vendors. The proportional performance method is used for fixed-price contracts because reasonably dependable estimates of the revenues and costs applicable to various stages of a contract can be made, based on historical experience and the terms set forth in the contract, and are indicative of the level of benefit provided to Juniper’s clients. In the event of a termination, fixed-price contracts generally provide for payment for services rendered up to the termination date. Service revenues also include reimbursements, which include reimbursement for travel and other out-of-pocket expenses, outside consultants, and other reimbursable expenses. The Company maintains accounts receivable allowances for estimated losses resulting from disputed amounts or the inability of Juniper’s customers to make required payments. Juniper identifies specific collection issues and establishes an accounts receivable allowance based on its historical collection experience, review of client accounts, current trends, and credit policy. If the financial condition of Juniper’s customers were to deteriorate or disputes were to arise regarding the services provided, resulting in an impairment of their ability or intent to make payment, additional allowances may be required. A failure to estimate accurately the accounts receivable allowances and ensure that payments are received on a timely basis could have a material adverse effect on Juniper’s business, financial condition, and results of operations. Juniper collects value added tax from its customers for revenues generated out of the United Kingdom for which the customer is not tax exempt and remits such taxes to the appropriate governmental authorities. Juniper presents its value added tax on a net basis; therefore, these taxes are excluded from revenues. Deferred Revenue The Company’s deferred revenue balance consists of the following at December 31, 2017 and 2016 (in thousands): As of December 31, 2017 2016 Product revenues $ 5,888 $ 4,647 Service revenues 253 385 Regional Growth Fund — 592 Total $ 6,141 $ 5,624 Amounts invoiced but not yet earned on product revenues are recorded as deferred revenue until the Company receives sell through information from Merck KGaA indicating the product has been sold through or otherwise disposed of. Amounts invoiced but not yet earned on service revenue are deferred until such time as performance is rendered or the obligation to perform the service is completed for service revenues. As part of the acquisition of Juniper Pharma Services, Juniper assumed a $2.5 million obligation under a grant arrangement with the Regional Growth Fund on behalf of the Secretary of State for Business, Innovation, and Skills in the United Kingdom. Juniper Pharma Services used this grant to fund the building of its second facility, which includes analytical labs, office space, and a manufacturing facility. As a part of the arrangement, Juniper Pharma Services was required to create and maintain certain full-time equivalent personnel levels through October 2017. The obligation ended in October 1, 2017 and the Company met all compliance requirements thru that date. Research and Development Costs Research and development consist of consultants, material costs, salaries and other personnel related expenses including stock-based compensation of employees and non-employees primarily engaged in research and development activities and materials used and other overhead expenses incurred. All research and development costs are expensed as incurred. Research and development costs that are paid in advance of performance are capitalized as prepaid expenses until incurred. Clinical trial expenses include expenses associated with clinical research organizations. The invoicing from clinical research organizations for services rendered can lag several months. Juniper accrues the cost of services rendered in connection with clinical research organizations activities based on its estimate of costs incurred. Juniper maintains regular communication with its clinical research organizations to assess the reasonableness of its estimates. In March 2015, the Company entered into an exclusive patent license agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital, pursuant to which Juniper has licensed the exclusive worldwide rights to Massachusetts General Hospital patent rights in a novel IVR technology for delivery of one or more pharmaceutical dosages and release rates in a single segmented ring. The Company is leveraging the technology to advance its IVR product candidates: JNP-0101, JNP-0201 and JNP-0301. In August 2016, the Company announced that the Phase 2b clinical trial evaluating COL-1077, 10% lidocaine bioadhesive vaginal gel, for the reduction of pain intensity in women undergoing an endometrial biopsy with tenaculum placement did not achieve its primary and secondary endpoints. The safety and pharmacokinetic (PK) profiles of COL-1077 were consistent with what has been observed in prior clinical trials of the lidocaine bioadhesive vaginal gel. Based on this study outcome the Company discontinued further development of COL-1077, with resources reallocated to its preclinical programs. In September 2017, the Company announced a reduction of approximately 8% of our workforce, primarily in the areas of new product research and development, in order to focus its resources on its core businesses. In addition, as part of its more focused research and development strategy, the Company completed its in vivo in vivo Stock-based compensation Under the Company’s stock-based compensation program, the Company periodically grants stock options and restricted stock to employees, directors and nonemployee consultants. The fair value of all awards is recognized in the Company’s statement of operations over the requisite service period for each award. Juniper follows the fair value recognition provisions of ASC 718, Stock Compensation Topic Equity – Equity Based Payments to Nonemployees Awards that vest as the recipient provides service are expensed on a straight-line basis over the requisite service period. Other awards, such as performance-based awards that vest upon the achievement of specified goals, are expensed if achievement of the specified goal is considered probable. The Company uses the Black-Scholes option pricing model to value its stock option awards which requires the Company make certain assumptions regarding the expected volatility of its common stock price, the expected term of the option grants, the risk-free interest rate and the dividend yield with respect to its common stock. Due to the lack of the Company’s own historical data, the Company elected to use the simplified method for “plain vanilla” options to estimate the expected term of the Company’s stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. The risk-free interest rate used for each grant is based on the U.S. Treasury yield curve in effect at the time of the grant for instruments with a similar expected life. The Company utilizes a dividend yield of zero based on the fact that the Company has no present intention to pay cash dividends. The Company did not consider any forfeiture rate assumption in its determination of stock-based compensation. The fair value of equity-classified awards to employees and directors are measured at fair value on the grant on the date the awards are granted. Awards to nonemployee consults are recorded at the grant date fair values and are re-measured at each balance sheet date until the recipient’s services are complete. During the years ended December 31, 2017, 2016 and 2015, the Company recorded the following stock-based compensation expense (in thousands): Years Ended December 31, 2017 2016 2015 Cost of revenues $ 120 $ 199 $ 79 Sales and marketing 47 50 38 Research and development 16 73 1,126 General and administrative 1,286 879 507 Total stock-based compensation $ 1,469 $ 1,201 $ 1,750 Stock-based compensation expense is allocated based upon the department of the employee to whom each award was granted. Expenses recognized in connected with the modification of awards in connection with the Company’s strategic restructuring are allocated to restructuring expense. No related tax benefit of the stock-based compensation expense has been recognized. As of December 31, 2017, total unamortized share-based compensation cost related to non-vested stock options and restricted stock was $2.5 million, which is expected to be recognized on a straight-line basis over a weighted average period of 2.7 years. Years Ended December 31, 2017 2016 2015 Risk free interest rate 1.45%-1.59% 0.85%-1.45% 0.87%-1.20% Expected term 4.5-4.75 years 4.75 years 4.56-4.75 years Dividend yield — — — Expected volatility 53.15%-55.20% 55.23%-79.29% 76.86%-83.09% Net (Loss) Income Per Common Share The calculation of basic and diluted (loss) income per common and common equivalent share is as follows (in thousands except for per share data): Years Ended December 31, 2017 2016 2015 Basic net (loss) income per common share Net (loss) income $ (2,060 ) $ 5,951 $ (1,496 ) Add: Excess of carrying value of Series C Preferred Stock over redemption value 459 — — Less: Preferred stock dividends (14 ) (28 ) (28 ) Net (loss) income applicable to common stockholders $ (1,615 ) $ 5,923 $ (1,524 ) Basic weighted average number of common shares outstanding 10,824 10,795 10,774 Basic net (loss) income per common share $ (0.15 ) $ 0.55 $ (0.14 ) Diluted net (loss) income per common share Net (loss) income applicable to common stock $ (1,615 ) $ 5,923 $ (1,524 ) Add: Preferred stock dividends — 28 — Net (loss) income applicable to dilutive common stock $ (1,615 ) $ 5,951 $ (1,524 ) Basic weighted average number of common shares outstanding 10,824 10,795 10,774 Effect of dilutive securities Dilutive preferred share conversions — 83 — Dilutive stock awards — 13 — — 96 — Diluted weighted average number of common shares outstanding 10,824 10,891 10,774 Diluted net (loss) income per common share $ (0.15 ) $ 0.55 $ (0.14 ) Basic net (loss) income per common share is computed by dividing the net (loss) income, less preferred dividends and adding the excess of carrying value of Series C Preferred Stock over redemption value recognized on the conversion of the Series C Preferred Stock, by the weighted-average number of shares of common stock outstanding during a period. The diluted net (loss) income per common share calculation gives effect to dilutive options, convertible preferred stock, and other potential dilutive common stock including selected restricted shares of common stock outstanding during the period. Diluted net (loss) income per common share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options, assuming the exercise of all in-the-money stock options. Common share equivalents have been excluded where their inclusion would be anti-dilutive. Shares to be issued upon the exercise of the outstanding options, convertible preferred stock and selected restricted shares of common stock excluded from the income per share calculation amounted to 1,981,934, 1,658,234 and 1,087,308 for the years ended December 31, 2017, 2016 and 2015, respectively, because the awards were anti-dilutive. Recent Accounting Pronouncements Adopted In March 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory To be adopted In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment . The standard simplifies the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. The ASU is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, and should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of this standard will not have an impact on our consolidated financial statements and related disclosures. In August 2016, the FASB issued ASU No. 2016-16, Classification of Certain Cash Receipts and Cash Payments , (“ASU 2016-16”), which amends the guidance of ASC No. 230 on the classification of certain items in the statement of cash flows. The primary purpose of ASU 2016-15 is to reduce the diversity in practice by making amendments that add or clarify the guidance on eight specific cash flow issues. ASU 2016-15 is effective for all fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. ASU 2016-15 should be applied retrospectively to all periods presented, but may be applied prospectively from the earliest practicable if retrospective application would be impracticable. The adoption of this standard will not have an impact on our consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	3. Goodwill and Intangible Assets Changes to goodwill during the years ended December 31, 2017 and 2016 were as follows (in thousands): Total Balance – December 31, 2015 $ 10,010 Translation adjustment (1,668 ) Balance – December 31, 2016 8,342 Translation adjustment 781 Balance – December 31, 2017 $ 9,123 Intangible assets consist of the following at December 31, 2017 and December 31, 2016 (in thousands): Trademark Developed Technology Customer Relationships Total Gross carrying amount – December 31, 2017 $ 300 $ 1,370 $ 1,240 $ 2,910 Translation adjustment (53 ) (198 ) (179 ) (430 ) Accumulated amortization (247 ) (839 ) (650 ) (1,736 ) Balance – December 31, 2017 $ — $ 333 $ 411 $ 744 Trademark Developed Technology Customer Relationships Total Gross carrying amount – December 31, 2016 $ 300 $ 1,370 $ 1,240 $ 2,910 Translation adjustment (53 ) (298 ) (270 ) (621 ) Accumulated amortization (247 ) (617 ) (456 ) (1,320 ) Balance – December 31, 2016 $ — $ 455 $ 514 $ 969 Prior to completing the triggering event based assessment of goodwill on September 18, 2017 under ASC 350, the Company assessed its long-lived assets under ASC 360-10-05, Impairment or Disposal of Long-Lived Assets Amortization expense related to the developed technology is classified as a component of cost of service revenues in the consolidated statements of operations. Amortization expense related to trademark and customer relationships is classified as a component of general and administrative expenses in the consolidated statements of operations. Acquired intangible assets are amortized over their estimated useful lives based on either the pattern in which the economic benefits of the intangible asset are consumed or on a straight-line method. The estimated useful life represents the anticipated term of the acquired intangible assets. The estimated useful lives for the trademark, developed technology and customer relationships are 3 years, 7 years and 7 years, respectively. The trademark intangible was fully amortized as of December 31, 2016. The weighted average amortization period in total is 6.6 years. Amortization expense for the years ended December 31, 2017, 2016 and 2015, was $0.3 million, $0.4 million and $0.4 million, respectively. As of December 31, 2017, amortization expense on existing intangible assets for the next four years is as follows (in thousands): Year Total 2018 $ 289 2019 262 2020 193 Total $ 744

Debt and other Contractual Obli

Debt and other Contractual Obligations	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Debt and other Contractual Obligations	4. Debt and other Contractual Obligations In September 2013, Juniper assumed debt of $3.9 million in connection with its acquisition of Juniper Pharma Services. Juniper Pharma Services entered into a Business Loan Agreement (“Loan Agreement”) covering three loan facilities (collectively referred to as the “original agreements”) with Lloyds TSB Bank (“Lloyds”), as administrative agent. In May 2017, Juniper Pharma Services repaid one of the existing loan facility upon which Juniper Pharma Services subsequently entered into a new loan facility with the same administrative agent for the same outstanding balance. The refinancing was accounted for as a modification with no resulting gain or loss. The remaining original agreements and the new agreement are collectively referred to as the “loan facilities”. As of December 31, 2017, the Company owed $2.4 million on the loan facilities. The loan facilities are each repayable by monthly installments, one started repayment in February 2013 and the remaining two commenced in October 2013. All facilities are due for repayment over periods ranging from 7-15 years from the date of drawdown. Two of the facilities bear interest at the Bank of England’s base rate plus 1.95% and 2.55%, respectively. The weighted average interest rate for these two facilities at December 31, 2017 was 2.45% and 3.05%, respectively. The third facility is a fixed rate agreement bearing interest at 2.99% per annum. The weighted average interest rate for the three loan facilities for the year ended December 31, 2017 was 2.76%. The loan facilities are secured by the mortgaged property and an unlimited lien on the other assets of Juniper Pharma Services. The loan facilities contain financial covenants that limit the amount of indebtedness Juniper Pharma Services may incur, requires Juniper Pharma Services to maintain certain levels of net worth, and restricts Juniper Pharma Services’ ability to materially alter the character of its business. As of December 31, 2017 the Company is in compliance with all of the covenants under the loan facilities. In September 2013, as part of the acquisition of Juniper Pharma Services, Juniper assumed a $2.5 million obligation under a grant arrangement with the Regional Growth Fund on behalf of the Secretary of State for Business, Innovation, and Skills in the United Kingdom. Juniper Pharma Services used this grant to fund the building of its second facility, which includes analytical labs, office space, and a manufacturing facility. As a part of the arrangement, Juniper Pharma Services was required to create and maintain certain full-time equivalent personnel levels through October 2017. The obligation ended on October 1, 2017. As of December 31, 2017, the Company’s obligation under the grant arrangement is complete and the Company all compliance requirements through October 1, 2017. The income from the Regional Growth Fund was recognized on a decelerated basis over the three-year term of the agreement. Other income associated with the Regional Growth Fund for the years ended December 2015, 2016 and 2017 were $0.5 million, $0.7 million and $0.6 million, respectively. Additionally, Juniper leases its U.S. corporate office under an operating lease. In October 2015, the Company entered into a lease agreement for its corporate office in Boston, Massachusetts. The initial term of the lease agreement is approximately 39 months and ends in 2019, which includes a three-month free rent period. In January and March 2017, the Company entered into loans of $0.9 million and $0.6 million, respectively, with payments thru March 2022 for equipment in its Nottingham, U.K. facility. The interest rate for the two loans was 2.09% at December 31, 2017. The transactions were considered failed sales-leaseback arrangements as the Company will obtain title to the equipment at the end of the term of the financing for little or no consideration. These failed sale-leaseback arrangements have been recorded as a component of long-term debt on the Company’s condensed consolidated balance sheets. The initial terms of the loans are 60 months. In December 2016, the Company entered into an API Supply Agreement for a manufacturer of progesterone under which the it has agreed to annual minimum volume commitments until December 2019. The Company’s significant outstanding contractual obligations relate to operating leases for the Company’s facilities and loan agreements. The Company’s facility leases are non-cancellable and contain renewal options. The Company’s future contractual obligations as of December 31, 2017 include the following (in thousands): Total 2018 2019 2020 2021 2022 Thereafter Operating lease obligations $ 517 $ 443 $ 74 $ — $ — $ — $ — Loan principal repayments 2,422 236 241 248 255 263 1,179 Capital lease obligations 1,377 311 324 338 351 53 — Minimum purchase obligation 5,720 3,861 1,859 — — — — Total $ 10,036 $ 4,851 $ 2,498 $ 586 $ 606 $ 316 $ 1,179 Rent expense was $0.4 million for December 31, 2017, $0.4 million for December 31, 2016, and $0.3 million for December 31, 2015. Interest expense, net was $0.1 million in each of the years ended December 31, 2017, 2016, and 2015.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Property and Equipment, Net	5. Property and Equipment, net Property and equipment consists of the following (dollars in thousands): Estimated Useful Life December 31, (Years) 2017 2016 Machinery and equipment 3-10 $ 12,358 $ 8,628 Furniture and fixtures 3-5 1,083 1,190 Computer equipment and software 3-5 628 538 Buildings Up to 39 7,995 7,310 Land Indefinite 513 469 Construction in-process 1,133 1,567 23,710 19,702 Less: Accumulated depreciation (8,481 ) (6,336 ) Total $ 15,229 $ 13,366 Depreciation expense was $1.9 million, $1.5 million and $1.5 million for each of the years ended December 31, 2017, 2016 and 2015, respectively. The net book value of property and equipment subject to lien under the debt agreement is $7.4 million and $5.5 million as of December 31, 2017 and 2016, respectively.

Accrued Expenses and Other

Accrued Expenses and Other	12 Months Ended
	Dec. 31, 2017
Payables And Accruals [Abstract]
Accrued Expenses and Other	6. Accrued Expenses and Other Accrued expenses and other consist of the following (in thousands): December 31, 2017 2016 Payroll $ 1,795 $ 1,643 Professional fees 2,006 1,074 Clinical studies 204 740 Other 1,361 1,814 Restructuring 249 - Total $ 5,615 $ 5,271

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes (Loss) income before income taxes consists of the following (in thousands): Year Ended December 31, 2017 2016 2015 Domestic $ (15,887 ) $ (2,090 ) $ (8,133 ) Foreign 13,641 8,132 6,642 (Loss) income before income taxes $ (2,246 ) $ 6,042 $ (1,491 ) The components of the (benefit) provision for income taxes are as follows (in thousands): Year Ended December 31, 2017 2016 2015 Current: Federal $ (46 ) $ 80 $ (9 ) State — 11 14 Foreign — — — Total current (46 ) 91 5 Deferred: Foreign (140 ) — — Total deferred (140 ) — — (Benefit) provision for income taxes $ (186 ) $ 91 $ 5 The reconciliation of the federal statutory rate to Juniper’s effective tax rate is as follows: Year Ended December 31, 2017 2016 2015 Federal income tax rate 34.0 % 34.0 % 34.0 % Foreign rate differential 182.7 % (49.6 )% 151.5 % State tax, net of federal benefit 10.1 13.4 (0.9 ) Permanent Items: Incentive stock options (2.5 ) 1.0 (14.9 ) Dividend from foreign subsidiary (165.8 ) 53.5 (79.8 ) Amortization of technical rights — (34.5 ) 23.4 Deferred adjustments 15.9 30.6 6.6 Foreign research and development relief 26.3 — — Change in U.S. Federal rate (970.4 ) — — Other (2.6 ) (1.1 ) (0.5 ) Effect of permanent differences (1,099.1 ) 49.5 (65.2 ) Effective income tax rate (872.3 ) 47.3 119.4 Change in valuation allowance 880.6 (45.8 ) (119.7 ) Effective income tax rate 8.3 % 1.5 % (0.3 )% The Company recorded an income tax benefit of $0.2 million as of December 31, 2017. This benefit is primarily attributable to an adjustment to its foreign income inclusion for U.S. tax purposes, which reduced the amount of alternative minimum tax recorded in the Company’s 2016 tax provision and the release of valuation allowance with respect to Alternative Minimum Tax (“AMT”) credit carryover in connection with the Tax Cuts and Jobs Act of 2017. Effects of the Tax Cuts and Jobs Act On December 22, 2017 President Donald Trump signed into U.S. law the Tax Cuts and Jobs Act of 2017 (“Tax Reform”). ASC Topic 740, Accounting for Income Taxes Given the significance of the legislation, the U.S. Securities and Exchange Commission (the "SEC") staff issued Staff Accounting Bulletin ("SAB") No. 118 (“SAB 118”), which allows registrants to record provisional amounts during a one year “measurement period” similar to that used when accounting for business combinations. However, the measurement period is deemed to have ended prior to the one year term when the registrant has obtained, prepared, and analyzed the information necessary to finalize its accounting. During the measurement period, impacts of the law are expected to be recorded at the time a reasonable estimate for all or a portion of the effects can be made, and provisional amounts can be recognized and adjusted as information becomes available, prepared, or analyzed. SAB 118 summarizes a three-step process to be applied at each reporting period to account for and qualitatively disclose: (1) the effects of the change in tax law for which accounting is complete; (2) provisional amounts (or adjustments to provisional amounts) for the effects of the tax law where accounting is not complete, but that a reasonable estimate has been determined; and (3) a reasonable estimate cannot yet be made and therefore taxes are reflected in accordance with the law prior to the enactment of the Tax Cuts and Jobs Act. ASC Topic 740, Income Taxes utilizing The re-measurement calculation is provisional as the Company continues to evaluate the provisions of the Tax Reform. As part of the Tax Reform, the U.S. corporate income tax rate applicable to the Company decreased from 34% to 21%. This rate change resulted in the remeasurement of the Company’s net deferred tax assets and liabilities as of December 31, 2017, the effect of which was completely offset by a change in the Company’s valuation allowance. The Tax Reform includes a one-time mandatory repatriation transition tax on the net accumulated earnings and profits of a U.S. taxpayer’s foreign subsidiaries. The Company has performed an estimated earnings and profits analysis. The current estimate of the transition tax results in no income inclusion to the Company. To the extent that a refinement is made that materially changes the estimate calculation, the inclusion should be fully offset by tax losses incurred by the Company. There should be no income tax effect in the current period. The calculation of earnings and profits is provisional and further time is needed for detailed refinement. Pursuant to the Tax Reform, AMT credit carryforwards will be eligible for a 50% refund through tax years 2018 through 2020. Beginning in tax year 2021, any remaining AMT credit carryforwards would be 100% refundable. As a result of these new regulations, the Company has released its valuation allowance of $0.1 million formerly reserved against its AMT credit carryforwards. The Company has recorded a current income tax receivable of $0.1 million and a non-current income tax receivable of $0.1 million in connection with this valuation allowance release in which the entire benefit of $0.2 million is being recorded as a component of Income tax (benefit) expense for the year ended December 31, 2017. The calculation related to AMT credit carryforwards is provisional as the Company continues to evaluate the provisions of the Tax Reform. Other significant provisions that are not yet effective but may impact income taxes in future years include: an exemption from U.S. tax on dividends of future foreign earnings, limitation on the current deductibility of net interest expense in excess of 30% of adjusted taxable income, a limitation of net operating losses generated after fiscal 2018 to 80% of annual income, an incremental tax (base erosion anti-abuse tax or “BEAT”) on excessive amounts paid to foreign related parties, and a minimum tax on certain foreign earnings in excess of 10% of the foreign subsidiaries tangible assets (i.e., global intangible low-taxed income or “GILTI”). Because of the complexity of the new provisions, the Company is continuing to evaluate how the provisions will be accounted for under the U.S. generally accepted accounting principles wherein companies are allowed to make an accounting policy election of either (i) account for GILTI as a component of tax expense in the period in which the Company is subject to the rules (the “period cost method”), or (ii) account for GILTI in the Company’s measurement of deferred taxes (the “deferred method”). Currently, the Company has not elected a method and will only do so after its completion of the analysis of the GILTI provisions and its election method will depend, in part, on analyzing its global income to determine whether the Company expects to have future U.S. inclusions in its taxable income related to GILTI and, if so, the impact that is expected. The Company operates in multiple countries. Accordingly, separate tax filings are required based on jurisdiction. Due to the separate tax filings of our U.S., U.K. and France jurisdictions, the Company has evaluated the need for a valuation allowance on a separate jurisdiction basis. As of December 31, 2017, the Company continues to maintain a full valuation allowance against all net deferred tax assets. The components of the Company’s net deferred tax assets and liabilities are as follows (in thousands): December 31, 2017 December 31, 2016 Deferred Tax Asset Net Operating Loss $ 37,168 $ 55,521 Tax Credits 1,846 2,034 Stock Based Compensation 900 997 Intangibles 489 843 Other 290 337 Subtotal 40,693 59,732 Less: Valuation Allowance (39,072 ) (58,983 ) Total Deferred Tax Assets 1,621 749 Deferred Tax Liabilities Fixed Assets (1,621 ) (749 ) Total Deferred Tax Liabilities (1,621 ) (749 ) Net Deferred Tax Asset $ — $ — In assessing the realizability of deferred tax assets, management considers positive and negative evidence to determine whether it is more likely than not that some portion or all deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax-planning strategies in making this assessment. Management believes it is more likely than not that the results of future operations will not generate sufficient taxable income in the U.S., U.K. and France in order to realize the full benefits of the deferred tax assets in the respective jurisdictions. As of December 31, 2017, the Company has federal and state U.S. tax net operating loss carryforwards of approximately $164.0 million and $20.0 million, respectively, which begin to expire in 2020 and 2018, respectively. The Company also has federal research and development credit carryforwards of approximately $1.8 million, which begin to expire in 2018. As of December 31, 2017, the Company has non-U.S., net operating loss carryforwards of approximately $11.5 million, with no expiration period. The Company also has non-U.S. research and development credit carryforwards of approximately $0.3 million, with no expiration period. Under Section 382 of the Internal Revenue Code of 1986, as amended, substantial changes in the Company's ownership may limit the amount of net operating loss carryforwards that could be utilized annually in the future to offset taxable income. Specifically, this limitation may arise in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. Any such annual limitation may significantly reduce the utilization of net operating loss carryforwards before they expire. The Company performed an analysis through June 30, 2014, and determined any potential ownership change under Section 382 during the year would not have a material impact on the future utilization of US net operating losses and tax credits. However, future transactions in the Company's common stock could trigger an ownership change for purposes of Section 382, which could limit the amount of net operating loss carryforwards and other attributes that could be utilized annually in the future to offset taxable income, if any. Any such limitation, whether as the result of sales of common stock by our existing stockholders or sales of common stock by the Company, could have a material adverse effect on results of operations in future years. The Company follows the provisions of FASB ASC 740, Accounting for Uncertainty in Income Taxes – An Interpretation of FASB No. 109 The Company files tax returns in the United States, United Kingdom, France and various state jurisdictions. All of the Company’s tax years remain open to examination by major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in past years may still be adjusted upon examination by the Internal Revenue Service or state and foreign tax authorities if they have or will be used in future periods. As of December 31, 2017, outside of Columbia Bermuda, the Company does not maintain accumulated earnings and profits in the foreign jurisdictions that it currently does business. The Company has repatriated current earnings from one of its foreign subsidiaries to the United States in 2017 and 2016. To the extent the Company has positive accumulated foreign earnings in the future, the Company will further assess its global business needs and decide whether or not it will permanently reinvest those earnings.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Shareholders' Equity	8. Shareholders’ Equity As of December 31, 2017, the Company had 150,000,000 authorized shares of common stock, $0.01 par value, of which 12,256,980 were issued and 10,844,113 were outstanding. As of December 31, 2017, the Company had 1,000,000 authorized Preferred Stock, $0.01 par value, of which none were issued and outstanding. Preferred Stock During the quarter ending June 30, 2017, the Company issued a Notice of Conversion to the holders of Series B and a Notice of Redemption to the holders of Series C giving notice that on June 30, 2017 (the “Redemption and Conversion Date”) all outstanding shares of the respective Preferred Stock issuance would be converted, as in the case of the Series B, or redeemed, as in the case of the Series C. The Series B, by its terms, automatically converted into shares of common stock, upon the occurrence of the event. On the Redemption and Conversion Date, each share of the 130 shares of Series B outstanding converted into 2.78 shares of common stock resulting in an issuance of 361 shares. The holders of each share of the 550 shares of Series C outstanding had the right to require the Company to redeem their shares in cash plus all accrued and unpaid dividends thereon the date such redemption is demanded. On the Redemption and Conversion Date, the Company paid to the holders of the Series C approximately $0.01 million and as a result of the transaction recorded the excess of the carrying value of Series C over redemption value of approximately $0.5 million to accumulated deficit for the year ended December 31, 2017. At December 31, 2017, there were no remaining outstanding shares of either the Series B or the Series C. In March 2002, the Company adopted a Stockholder Rights Plan (the “Rights Plan”) designed to protect company stockholders in the event of takeover activity that would deny them the full value of their investment. The Rights Plan was not adopted in response to any specific takeover threat. In adopting the Rights Plan, the Board declared a dividend distribution of one preferred stock purchase right for each outstanding share of common stock of the Company, payable to stockholders of record at the close of business on March 22, 2002. The rights will become exercisable only in the event, with certain exceptions, a person or group of affiliated or associated persons acquires a specified amount (the “Specified Amount”) (originally 15%) or more of the Company’s voting stock, or a person or group of affiliated or associated persons commences a tender or exchange offer which, if successfully consummated, would result in such person or group owning the Specified Amount or more of the Company’s voting stock. Each right, once exercisable, will entitle the holder (other than rights owned by an acquiring person or group) to buy one one-thousandth of a share of a series of the Company’s Series D Junior Participating Preferred Stock at a price of $30 per one-thousandth of a share, subject to adjustments. In addition, upon the occurrence of certain events, holders of the rights (other than rights owned by an acquiring person or group) would be entitled to purchase either the Company’s preferred stock or shares in an “acquiring entity” at approximately half of market value. Further, at any time after a person or group acquires the Specified Amount or more (but less than 50%) of the Company’s outstanding voting stock, subject to certain exceptions, the Board of Directors may, at its option, exchange part or all of the rights (other than rights held by an acquiring person or group) for shares of the Company’s common stock having a fair market value on the date of such acquisition equal to the excess of (i) the fair market value of preferred stock issuable upon exercise of the rights over (ii) the exercise price of the rights. The Company generally will be entitled to redeem the rights at $0.01 per right at any time prior to the close of business on the tenth day after there has been a public announcement of the beneficial ownership by any person or group of the Specified Amount or more of the Company’s voting stock, subject to certain exceptions. In November 2010, the Board of Directors of the Company adopted an amendment and restatement (the “Amendment”) of the Rights Plan, dated as of March 13, 2002 (the “Original Rights Agreement”), between the Company and American Stock Transfer & Trust Company, LLC, as successor rights agent (as amended, the “Rights Plan”). In general, the Amendment leaves the Original Rights Agreement unchanged in all material respects, other than changing the trigger for the Rights becoming exercisable from 15% to 4.99% of the outstanding Voting Rights (as defined in the Rights Plan), expanding the concept of “beneficial ownership” to include shares owned (including those owned indirectly and constructively) under Section 382 of the Code and modifying the provisions relating to the exchange of Rights for common stock. The Company adopted the Amendment to preserve the value of the Company’s net operating loss carry forwards (the “Tax Benefits”), because its ability to fully use the Tax Benefits on an annual basis to offset future income may be substantially limited if the Company experiences an “ownership change” for purposes of Section 382 of the Internal Revenue Code of 1986 (the “Code”). Generally, the Company would experience an “ownership change” under Section 382 of the Code if a greater than 50 percentage point change in ownership of the Voting Stock (as defined in the Rights Plan and described below) by stockholders who beneficially own (or who are deemed to own) 5% or more of the Company’s Voting Stock occurs over a rolling three year period. In September 2011, the Company and American Stock Transfer and Trust Company, LLC, as rights agent, further amended the Rights Plan to extend the expiration date of the rights from March 12, 2012 to July 3, 2013. In March 2013, the Company further amended the Rights Plan to extend the expiration date from July 3, 2013, to July 3, 2016. No extension of the Rights Plan was made subsequent to that period.

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	9. Stock-based Compensation Common Stock The Company granted 66,234, 42,203 and 13,106 shares of restricted stock to the Company’s independent directors during the years ended December 31, 2017, 2016 and 2015, respectively. Stock Incentive Plan In May of 2008, the Company adopted the 2008 Long-term Incentive Plan (“2008 Plan”) which provides for the grant of stock options, stock appreciation rights and restricted stock to certain designated employees of the Company, non-employee directors of the Company and certain other persons performing significant services for the Company as designated by the Compensation Committee of the Board of Directors. At December 31, 2014, the number of common shares reserved for issuance under the 2008 plan was 1,250,000. Options granted under the plan vest either (i) over a 48-month period at the rate of 25% each year until fully vested or (ii) over a vesting period determined by the Board of Directors. This plan was replaced in April 2015 by the 2015 Long term-Incentive Plan (“2015 Plan”) and all remaining shares were made available under this plan. At December 31, 2015, the number of common shares and restricted stock reserved for issuance under the 2015 plan was 1,000,000 and 200,000, respectively. Options granted under the plan vest either (i) over a 48-month period at the rate of 25% each year until fully vested (ii) over a 48-month period at the rate of 6.25% each quarter until fully vested or (iii) over a vesting period determined by the Board of Directors. This plan was replaced in May 2016 by the 2015 Amended and Restated Long-term Incentive Plan (“Amended and Restated 2015 Plan”) and all remaining shares were made available under the Amended and Restated 2015 Plan. As of December 31, 2017, there were 1,861,142 shares available for future grant under the Amended and Restated 2015 Plan Stock Incentive Plan – Stock Options The Company’s stock options have a maximum term of 10 years from the date of grant. Options granted prior to 2006 have a 10-year term. Since 2006, the Company has been granting stock options with a 7-year term. A following table summarizes stock option activity during the year ended December 31, 2017: Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (year) Aggregate Intrinsic Value (in thousands) Outstanding, December 31, 2016 1,516,059 $ 7.25 5.19 $ 48 Granted 680,400 5.17 Exercised — — Forfeited (394,409 ) 6.71 Outstanding, December 31, 2017 1,802,050 $ 6.59 4.86 $ 8 Vested 822,736 7.19 3.85 — Unvested 979,314 6.08 5.71 8 Vested or expected to vest, December 31, 2017 1,802,050 $ 6.59 4.86 $ 8 Exercisable, December 31, 2017 822,736 $ 7.19 3.85 Juniper granted 680,400, 657,500 and 387,000 stock options to employees during the years ended December 31, 2017, 2016 and 2015, respectively. Cash received from option exercises was $0.1 million during the year ending December 31, 2015. No options were exercised in the year ended December 31, 2017 and 2016. The Company uses the Black-Scholes option pricing model to determine the estimated fair value for stock-based awards. The Black-Scholes option pricing model requires the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The weighted-average fair value of the options granted to employees during the years ended December 31, 2017, 2016 and 2015 was $2.43, $4.66 and $4.38, respectively based on the following assumptions: Years Ended December 31, 2017 2016 2015 Risk free interest rate 1.45%-1.59% 0.85%-1.45% 0.87%-1.20% Expected term 4.5-4.75 years 4.75 years 4.56-4.75 years Dividend yield — — — Expected volatility 53.15%-55.20% 55.23%-79.29% 76.86%-83.09% As of December 31, 2017, there was $2.5 million of total unrecognized compensation costs related to non-vested options. The remaining cost is expected to be recognized over a weighted average period of 2.7 years. The Company records stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options, which is re-measured over the graded vesting term resulting in periodic adjustments to stock-based compensation expense. During 2017 and 2016, no stock options were granted by the Company to non-employees. The stock-based compensation expense recorded for non-employees is primarily reflected in the research and development line of the statement of operations. The non-employee options reflected in the research and development line are re-measured on a quarterly basis from the date of grant. The Company recorded a reduction of stock-based compensation expense for non-employees of $0.1 million for each of the years ended December 31, 2017 and 2016, as a result of impacts of changes in the fair value. Stock-based compensation recorded for non-employees was $1.1 million in the year ended December 31, 2015. No tax benefit has been recognized due to the net tax losses during the periods presented. The weighted-average fair value of the options granted to non-employees during the year ended December 31, 2015 was $4.52 based on the following assumptions: 2015 Risk free interest rate 1.47%-1.54% Expected term 7 years Dividend yield — Expected volatility 82.88%-83.09% Stock Option Plan – Restricted Stock The Company periodically grants awards of restricted stock to employees. Restricted stock grants consist of grants of the Company’s common stock that may vest in the future. The Board has set a one, two, or four year vesting period for most of the issued restricted shares except annual grants to independent Directors which vest at the next annual meeting of stockholders. The fair value of each restricted share grant is equal to the market price of the Company’s common stock at the date of grant. Expense relating to restricted shares is recorded at the closing price on the grant date and amortized ratably over the vesting period. A summary of the Company’s restricted stock activity and related information for the year ended December 31, 2017 is as follows: Shares Weighted Average Grant Date Fair Value Unvested, December 31, 2016 40,933 $ 7.42 Granted 118,934 $ 5.03 Vested (40,933 ) $ 7.42 Forfeited (15,500 ) $ 5.15 Unvested, December 31, 2017 103,434 $ 5.01 As of December 31, 2017, there was $0.3 million of total unrecognized compensation costs related to non-vested restricted share-based compensation. The remaining cost is expected to be recognized over a weighted average period of approximately 2.1 years. The total fair value of shares vested during the year ended December 31, 2017 was $0.3 million. Juniper grants performance-based restricted stock units to employees which vest upon the occurrence of certain operational and strategic events that were determined by the Company’s Board of Directors. A summary of the Company’s performance-based restricted stock activity for the year ended December 31, 2017 is as follows: Performance-based Restricted Stock Units Unvested, December 31, 2016 — Granted 186,000 Vested — Forfeited (109,550 ) Unvested, December 31, 2017 76,450 No performance-based restricted stock units were awarded during the year ended December 31, 2016. None of the outstanding performance-based restricted stock units were deemed probable of vesting at December 31, 2017. On January 8, 2018, the Company announced the 4.5-year extension of its supply agreement for Crinone with an affiliate of Merck KGaA, Darmstandt, Germany. On February 7, 2018, the Company’s Compensation Committee of the Board of Director approved the vesting of 27,800 awards affiliated with this performance condition and as a result the Company will record a charge to stock compensation expense during the first quarter of 2018 totaling $0.2 million.

Legal Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Legal Proceedings	10 . Legal Proceedings Claims and lawsuits are filed against the Company from time to time. Although the results of pending claims are always uncertain, the Company believes that it has adequate reserves or adequate insurance coverage in respect of these claims, but no assurance can be given as to the sufficiency of such reserves or insurance coverage in the event of any unfavorable outcome resulting from these actions.

Segments and Geographic Informa

Segments and Geographic Information	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Segments and Geographic Information	11 . Segments and Geographic Information The Company and its subsidiaries currently operate in two segments: product and service. The product segment oversees the supply chain and manufacturing of Crinone, the Company’s sole commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services for the Company’s customers as well as characterizing and developing pharmaceutical product candidates for the Company’s internal programs and managing certain preclinical activities including manufacturing of the Company’s pipeline products. In September 2013, the Company acquired Juniper Pharma Services, a U.K.-based provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry. The Company has integrated its supply chain management for its sole commercialized product, Crinone into those operations and have therefore sought to capture synergies by transferring all operational activities related to its historic business. The Company owns certain plant and equipment physically located at third-party contractor facilities in the United Kingdom and Switzerland. The Company conducts its advanced formulation, analytical and consulting services through its subsidiary, Juniper Pharma Services. The Company’s largest customer, Merck KGaA, utilizes a Switzerland-based subsidiary to acquire product from the Company, which it then sells throughout the world excluding the U.S. The Company’s primary domestic customer, Allergan, is responsible for the commercialization and sale of progesterone products in the United States. In November 2016, the Company entered into an agreement with Allergan to monetize future royalty payments. Under the agreement, the Company received a one-time payment of $11.0 million representing all future U.S. royalty amounts payable. This amount was included in revenue in the year ended December 31, 2016. The following tables show selected information by geographic area (in thousands): Revenues: Year Ended December 31, 2017 2016 2015 United States $ 10,464 $ 19,955 $ 7,677 Switzerland 33,264 27,302 23,139 United Kingdom 3,559 4,632 4,422 Other countries 2,692 2,684 3,049 Subtotal international 39,515 34,618 30,610 Total $ 49,979 $ 54,573 $ 38,287 Total assets: December 31, 2017 2016 United States $ 21,683 $ 21,423 Switzerland 1,366 4,673 United Kingdom 38,129 31,288 Other countries 42 187 Total $ 61,220 $ 57,571 Long-lived assets: December 31, 2017 2016 United States $ 523 $ 663 Switzerland 535 369 United Kingdom 15,064 13,468 Other countries 2 2 Total $ 16,124 $ 14,502 The following summarizes other information by segment for the year ended December 31, 2017 (in thousands): Product Service Total Revenues Product revenues $ 32,688 $ — $ 32,688 Service revenues — 17,291 17,291 Total revenues 32,688 17,291 49,979 Cost of product revenues 19,013 — 19,013 Cost of service revenues — 9,948 9,948 Total cost of revenues 19,013 9,948 28,961 Gross profit $ 13,675 $ 7,343 $ 21,018 Total operating expenses 24,881 Total non-operating income 1,617 Income before income taxes $ (2,246 ) The following summarizes other information by segment for the year ended December 31, 2016 (in thousands): Product Service Total Revenues Product revenues $ 27,211 $ — $ 27,211 Service revenues — 13,065 13,065 Royalties 14,297 — 14,297 Total revenues 41,508 13,065 54,573 Cost of product revenues 15,595 — 15,595 Cost of service revenues — 8,698 8,698 Total cost of revenues 15,595 8,698 24,293 Gross profit $ 25,913 $ 4,367 $ 30,280 Total operating expenses 25,001 Total non-operating income 763 Loss before income taxes $ 6,042 The following summarizes other information by segment for the year ended December 31, 2015 (in thousands): Product Service Total Revenues Product revenues $ 22,891 $ — $ 22,891 Service revenues — 11,651 11,651 Royalties 3,745 — 3,745 Total revenues 26,636 11,651 38,287 Cost of product revenues 13,053 — 13,053 Cost of service revenues — 8,361 8,361 Total cost of revenues 13,053 8,361 21,414 Gross profit $ 13,583 $ 3,290 $ 16,873 Total operating expenses 18,746 Total non-operating income 382 Income before income taxes $ (1,491 ) Our chief operating decision maker evaluates the performance of our product and service segments based on revenue and gross profit. Our chief operating decision maker does not review our assets, operating expenses or non-operating income and expenses by business segment at this time. Therefore, such allocations by segment are not provided. Customer Concentration The following table presents information about Juniper’s revenues by customer, including product sales, royalty and license revenue and service revenues for each customer accounting for 10% or more of consolidated revenues in any of the three years ended December 31 by segment: Product Year Ended December 31, 2017 2016 2015 Merck KGaA 100 % 66 % 86 % Allergan - 34 14 Total 100 % 100 % 100 % At December 31, 2017 and 2016, Merck KGaA accounted for 100% of the product segment accounts receivable. Service One of our customers in our service segment represented 33% of total service revenue for the year ended December 31, 2017. No other customers accounted for 10% or more of total service revenue for the year ended December 31, 2017. No customers accounted for 10% or more of total service revenue for the years ended December 31, 2016 and 2015. At December 31, 2017, one customer accounted for 53% of total service segment net accounts receivable. At December 31, 2016, two customers accounted for 18% and 13% of total service segment net accounts receivable. At December 31, 2015 one customer accounted for 18% of total service segment accounts receivable. Patent Expiration Juniper is a pharmaceutical company focused on developing novel intra-vaginal therapeutics that address unmet medical needs in women’s health. All of the Company’s product sales are outside the United States. The patent for Crinone has expired in all countries other than Argentina. This product accounts for approximately 65% of the Company’s revenues and a higher percentage of gross profit. Sources of Supply The major raw materials the Company uses in its products and product candidates are polycarbophil and progesterone. Medical grade, cross-linked polycarbophil, the polymer used in the BDS-based product is currently available from only one supplier, Lubrizol Inc. (“Lubrizol”). The Company believes that Lubrizol will supply as much of the material as it requires because the product ranks among the highest value-added uses of the polymer. In the event that Lubrizol cannot or will not supply enough polycarbophil to satisfy the Company’s needs, however, Juniper will be required to seek alternative sources of supply. Only one supplier of progesterone for Crinone is approved by regulatory authorities outside the United States. Juniper has not experienced production delays due to shortages of progesterone. Beginning in 2017, this supplier increased the price for its progesterone. The second supplier has been approved in several countries and is in the regulatory approval process in numerous other countries. The Company expects to receive regulatory approval for this second supplier in the countries where it sells Crinone within the next two years.

Quarterly Financial Information

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (Unaudited)	12 . Quarterly Financial Information (Unaudited) The following table sets forth specific unaudited consolidated quarterly statement of operations data for the eight quarters ended December 31, 2017 (in thousands). This information is unaudited, but in the opinion of management, it has been prepared on the same basis as the audited consolidated financial statements and all necessary adjustments, consisting only of normal recurring adjustments, have been included in the amounts stated below to state fairly the unaudited consolidated quarterly results of operations. The results of operations for any quarter are not necessarily indicative of the results of operations for any future period. First Quarter Second Quarter Third Quarter Fourth Quarter 2017 Revenues $ 11,247 $ 13,956 $ 12,986 $ 11,790 Gross profit 4,691 6,306 5,267 4,754 Operating expenses 6,146 6,662 6,802 5,271 (Loss) income from operations (1,455 ) (356 ) (1,535 ) (517 ) Net (loss) income (1,441 ) (376 ) (1,410 ) 1,167 (Loss) income per common share: Basic $ (0.13 ) $ 0.01 $ (0.13 ) $ 0.11 Diluted $ (0.13 ) $ (0.03 ) $ (0.13 ) $ 0.11 First Quarter Second Quarter Third Quarter Fourth Quarter 2016 Revenues $ 10,477 $ 11,610 $ 11,556 $ 20,930 Gross profit 4,127 5,143 5,851 15,159 Operating expenses 5,865 7,420 5,674 6,042 (Loss) income from operations (1,738 ) (2,277 ) 177 9,117 Net (loss) income (1,643 ) (2,268 ) 248 9,614 (Loss) income per common share: Basic $ (0.15 ) $ (0.21 ) $ 0.02 $ 0.89 Diluted $ (0.15 ) $ (0.21 ) $ 0.02 $ 0.88 The explanation for major variances from the fourth quarter for the year ended December 31, 2016 are: 1. In the fourth quarter of 2016, the Company entered into an agreement with Allergan to monetize future royalty payments due to us. Under the agreement, we received a one-time non-refundable payment of $11.0 million in exchange for which Allergan will no longer be required to make future royalty payments to us

Restructuring Charges

Restructuring Charges	12 Months Ended
	Dec. 31, 2017
Restructuring And Related Activities [Abstract]
Restructuring Charges	13. Restructuring Charges In September 2017, the Company announced a corporate reprioritization which aimed to re-focus its resources on the core businesses of Crinone progesterone gel and JPS and reduce expenditures on research and development activities associated with the Company’s IVR program with the goal of potentially identifying a partner for one or more of its IVR product candidates. As a result, during the fiscal year ended December 31, 2017, the Company incurred approximately $0.8 million in restructuring charges. The Company accounted for these actions in accordance with ASC 420, Exit or Disposal Cost Obligations The following table summarizes the components of the Company’s restructuring activity recorded in the accompanying balance sheet (in thousands): Amounts accrued at December 31, 2016 Expense incurred during the year ended December 31, 2017 Amounts paid during the year ended December 31, 2017 Amounts accrued at December 31, 2017 Employee severance, benefits and related costs $ — $ 412 $ (340 ) $ 72 Obligations under manufacturing and development contracts — 296 (13 ) 283 $ — $ 708 $ (353 ) $ 355 In addition, approximately $17,000 in stock-based compensation expense associated with the modification of the exercise period on options held by an executive, approximately $14,000 related to fixed asset impairments resulting from the discontinuation of use on assets associated with programs terminated and approximately $37,500 in prepaid amortization associated with manufacturing contracts were recorded to Restructuring charges. In total, for the year ended December 31, 2017, the Company incurred $0.8 million in restructuring charges. No significant additional charges are anticipated relating to this restructuring plan. The Company expects to pay approximately $0.2 million and $0.1 million in 2018 and beyond, respectively.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries; Columbia Laboratories Bermuda Ltd., Juniper Pharmaceuticals France SARL, Juniper Pharmaceuticals UK Ltd., and Juniper Pharma Services Ltd. All significant intercompany balances and transactions have been eliminated in consolidation.
Segment Information	Segment information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. Juniper’s Chief Executive Officer has been identified as its CODM and evaluates the company’s performance and allocates resources based upon revenue and gross profit. The Company has concluded, based upon financial information regularly provided and reviewed, that there are two operating and reporting segments; product and services. Juniper’s CODM does not review its assets, operating expenses or non-operating income and expenses by business segment.
Management Estimates	Management Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to revenue recognition, sales return reserves, allowance for doubtful accounts, inventory reserves, impairment analysis of goodwill and intangibles including their useful lives, research and development accruals, deferred tax assets, liabilities and valuation allowances, and fair value of stock options. On an ongoing basis, management evaluates its estimates. Actual results could differ from those estimates.
Foreign Currency	Foreign Currency The assets and liabilities of the Company’s subsidiaries in the United Kingdom and France are translated into U.S. dollars at current exchange rates at the end of the period and revenue and expense items are translated at average rates of exchange prevailing during the period. The functional currency of these subsidiaries is considered to be the local currency for each entity and, accordingly, translation adjustments for these subsidiaries are included in accumulated other comprehensive income (loss) within stockholders’ equity. Certain intercompany and third-party foreign currency-denominated transactions generated foreign currency remeasurement losses of approximately $0.6 million, $0.2 million and $70,000 during the years ended December 31, 2017, 2016 and 2015, respectively, which are included in other expense, net in the consolidated statements of operations.
Cash Equivalents	Cash Equivalents The Company considers all investments purchased with an original maturity of three months or less to be cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported values. Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 820, Fair Value Measurement and Disclosures, Level 1: Quoted prices in active markets for identical assets and liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value of cash and cash equivalents are classified as Level 1 at December 31, 2017 and 2016. Some of the estimates and assumptions in the Company's goodwill impairment assessment include: the amount and timing of the projected net cash flows, the discount rate, and the tax rate. The fair value of accounts receivable and accounts payable approximate their carrying amount. The Company’s long-term debt is carried at amortized cost, which approximates fair value based on current market pricing of similar debt instruments and is categorized as a Level 2 measurement. The Company did not have transfers of financial assets between Level 1 and Level 2.
Inventories	Inventories Inventories are stated at the lower of cost (first-in, first-out) or market, determined on a first-in, first-out method. We monitor standard costs on a monthly basis and update them annually as necessary to reflect change in raw material costs and labor and overhead rates. Components of inventory cost include materials, labor and manufacturing overhead. Inventories consist of the following (in thousands): December 31, 2017 2016 Raw materials $ 1,921 $ 856 Work in process 3,299 3,806 Finished goods 1,106 959 Total $ 6,326 $ 5,621 We provide inventory allowances when conditions indicate that the selling price could be less than cost due to physical deterioration, usage, obsolescence, reductions in estimated future demand and reductions in selling prices. We balance the need to maintain strategic inventory levels with the risk of obsolescence due to changing technology and customer demand levels. Unfavorable changes in market conditions may result in a need for additional inventory reserves that could adversely impact our gross margins. Reserves for excess and obsolete inventory were $0.5 million and $45,000 at December 31, 2017 and 2016, respectively. During the fiscal year ended December 31, 2017, the Company recorded charges in the condensed consolidated statements of operations for excess and obsolete inventory of $0.4 million. No charges were recorded for the fiscal year ended December 31, 2016. Unfavorable changes in market conditions may result in a need for additional inventory reserves that could adversely impact the Company’s gross margins.
Accounts Receivable, Net of Allowances	Accounts Receivable, net of allowances Accounts receivable are reported at their outstanding unpaid principal balances reduced by allowances for doubtful accounts. The Company estimates doubtful accounts based on its historical collection experience, factors related to specific customers’ ability to pay and current economic trends. The Company writes off accounts receivable against the allowance when a balance is determined to be uncollectable. Accounts receivable allowance activity consisted of the following for the years ended December 31 (in thousands): 2017 2016 2015 Balance at beginning of year $ 37 $ 263 $ 358 Additions 78 — — Deductions — (226 ) (95 ) Balance at end of year $ 115 $ 37 $ 263 Juniper’s accounts receivable balance, net of allowance for doubtful accounts, was $4.7 million as of December 31, 2017, and $6.6 million as of December 31, 2016. Included in the accounts receivable balance at December 31, 2017 and 2016 were $3.0 million and $1.3 million of unbilled accounts receivable, respectively. Juniper’s unbilled accounts receivable is derived from services performed that have not been billed as of the balance sheet date.
Property and Equipment, Net	Property and Equipment, net Property and equipment is stated at cost less accumulated depreciation. Leasehold improvements are amortized over the lesser of the useful life or the term of the leases. Depreciation is computed on the straight-line basis over the estimated useful lives of the respective assets, as follows: Years Machinery and equipment 3-10 Furniture and fixtures 3-5 Computer equipment and software 3-5 Buildings Up to 39 Land Indefinite Costs of major additions and improvements are capitalized and expenditures for maintenance and repairs that do not extend the life of the assets are expensed. Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are eliminated from the accounts and any resultant gain or loss is credited or charged to operations. Juniper continually evaluates whether events or circumstances have occurred that indicate that the remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. Juniper evaluates the realizability of its long-lived assets based on profitability and cash flow expectations for the related asset. Any write-downs are treated as permanent reductions in the carrying amount of the assets. Based on this evaluation, Juniper believes, as of each balance sheet date presented, none of Juniper’s long-lived assets were impaired.
Concentration of Risk	Concentration of Risk As of December 31, 2017, the Company has one major customer. See Note 11 of the Company’s consolidated financial statements for customer and product concentrations. The Company depends on one supplier for a key excipient (ingredient) used in its products and one supplier for one of the active pharmaceutical ingredients.
Goodwill	Goodwill Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination. The Company does not amortize its goodwill, but instead tests for impairment annually in the fourth quarter and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than its carrying value of the asset. In September 2017, the Company announced a corporate reprioritization to allow it to focus its resources on the core businesses of Crinone progesterone gel and Juniper Pharma Services. The Company considered the announcement to be a triggering event requiring a test for impairment under ASC 350, Goodwill and Other Intangibles In accordance with ASC 350, the Company uses the two-step approach for each reporting unit. The first step compares the carrying amount of the reporting unit to its estimated fair value (Step 1) utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated using a risk-adjusted discount rate. To the extent that the carrying value of the reporting unit exceeds its estimated fair value, a second step is performed, wherein the reporting unit’s carrying value is compared to the implied fair value (Step 2). To the extent that the carrying value of goodwill exceeds the implied fair value of goodwill, impairment exists and must be recognized. The Company has concluded that its business represents two reporting units for goodwill impairment testing, which are product and service. The Company’s goodwill is assigned to its service reporting unit. The Company has performed tests for impairment as of September 18, 2017, the date of the triggering event, and October 1, 2017, the date of the annual test, and has determined that goodwill is not impaired as of either date. Furthermore, the Company also concluded that no triggering events have occurred subsequent to the most recent Step 1 goodwill impairment test.
Intangible Assets	Intangible Assets The Company capitalizes and includes in intangible assets the costs of trademark, developed technology and customer relationships. Intangible assets are recorded at fair value at the time of their acquisition and stated net of accumulated amortization. The Company amortizes its intangible assets that have finite lives using either the straight-line or accelerated method, based on the useful life of the asset over which it is expected to be consumed utilizing expected undiscounted future cash flows. Amortization is recorded over the estimated useful lives ranging from 3 to 7 years. The Company evaluates the realizability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, the Company estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, the Company uses market participant assumptions pursuant to ASC 820, Fair Value Measurements
Income Taxes	Income Taxes Deferred tax assets or liabilities are determined based on timing differences between when income and expense items are recognized for financial statement purposes versus when they are recognized for tax purposes, as measured by enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be settled. A valuation allowance is provided against deferred tax assets in circumstances where management believes it is more likely than not that all or a portion of the assets will not be realized. The Company has provided a full valuation allowance in the amount of $39.1 million and $59.0 million against its net domestic and foreign deferred tax assets as of December 31, 2017 and 2016, respectively.
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Changes to accumulated other comprehensive loss during the year ended December 31, 2017 were as follows (in thousands): Translation Adjustment Balance – December 31, 2016 $ (5,028 ) Current period other comprehensive income (1,871 ) Balance – December 31, 2017 $ (3,157 ) No reclassification from accumulated other comprehensive loss to net (loss) income occurred during the year ended December 31, 2017.
Revenue Recognition	Revenue Recognition Revenues include product revenues, which primarily consist of sales of Crinone to Merck KGaA, royalty revenues, which primarily consisted of royalty revenues from Allergan on sales of Crinone until the November 2016 monetization agreement, and service revenues, which primarily consist of analytical and consulting services, pharmaceutical development and clinical trial manufacturing services and other revenues. Product Revenue Revenues from the sale of products are recognized when all of the following criteria are met: persuasive evidence of a sales arrangement exists; delivery has occurred or services have been rendered; the price is fixed or determinable; and collectability is reasonably assured. Selling prices to Merck KGaA for Crinone (progesterone gel) are determined on an annual and country-by-country basis and are the greater of (i) a percentage of Merck KGaA’s net estimated selling price, or (ii) Juniper’s direct manufacturing cost plus 20% and are invoiced to Merck KGaA upon shipment. Juniper records revenue at the minimum selling price, which is Juniper’s direct manufacturing cost plus 20% at the time of shipment to Merck KGaA as that amount is considered fixed or determinable. The Company records deferred revenue related to amounts invoiced above the minimum selling price. Upon receiving sell through information from Merck KGaA on a quarterly and country-by-country basis, the Company records an adjustment to increase revenue to reflect the difference between Merck KGaA’s actual net selling price and the minimum price recorded at the time of shipment. Any difference between the amounts invoiced at Merck KGaA’s estimated net selling price and Merck KGaA’s actual net selling price are billed or credited to Merck KGaA in the quarter the product is sold through by Merck KGaA. Accordingly, product revenue in each period includes both an amount for product shipped to Merck KGaA in the current period recognized at the minimum purchase price as well as an amount for product shipped by Merck KGaA to its customers in the current period equal to the difference between Merck KGaA’s actual net selling price and the minimum purchase price. Merck KGaA is also entitled to a volume discount based on annual purchases. The Company records reserves against revenue on a quarterly basis to reflect the volume discount expected to be earned by Merck KGaA during the year. In April 2013, Juniper’s license and supply agreement with Merck KGaA for the sale of Crinone outside the United States was renewed for an additional five-year term, extending the expiration date to May 19, 2020. In January 2018, the Company announced the extension of the supply agreement for an additional 4.5-years through at least December 31, 2024. Royalty revenues, based on sales by licensees, are recorded as revenues when those sales are made by the licensees. In November 2016, the Company received a one-time payment of $11.0 million in exchange for which Allergan will no longer be required to make future royalty payments due to Juniper. Service Revenue The professional service contracts that Juniper enters into and operates under specify whether the engagement will be billed on a time-and-materials or a fixed-price basis. These engagements generally last three to six months, although some of Juniper’s engagements can be longer in duration. Juniper recognizes substantially all of the Company’s professional services revenues under written contracts when the fee is fixed or determinable, as the services are provided, and only in those situations where collection from the client is reasonably assured. In certain cases, Juniper bills clients prior to work being performed, which requires Juniper to defer revenue in accordance with U.S. GAAP. Revenues from time-and-materials service contracts are recognized as the services are performed based upon hours worked and contractually agreed-upon hourly rates, as well as indirect fees based upon hours worked. Service revenues from a majority of Juniper’s fixed-price engagements are recognized on a proportional performance method based on the ratio of costs incurred, substantially all of which are labor-related, to the total estimated project costs. Project costs are classified in costs of services and are based on the direct salary of the employees on the engagement plus all direct expenses incurred to complete the engagement, including any amounts billed to Juniper by its vendors. The proportional performance method is used for fixed-price contracts because reasonably dependable estimates of the revenues and costs applicable to various stages of a contract can be made, based on historical experience and the terms set forth in the contract, and are indicative of the level of benefit provided to Juniper’s clients. In the event of a termination, fixed-price contracts generally provide for payment for services rendered up to the termination date. Service revenues also include reimbursements, which include reimbursement for travel and other out-of-pocket expenses, outside consultants, and other reimbursable expenses. The Company maintains accounts receivable allowances for estimated losses resulting from disputed amounts or the inability of Juniper’s customers to make required payments. Juniper identifies specific collection issues and establishes an accounts receivable allowance based on its historical collection experience, review of client accounts, current trends, and credit policy. If the financial condition of Juniper’s customers were to deteriorate or disputes were to arise regarding the services provided, resulting in an impairment of their ability or intent to make payment, additional allowances may be required. A failure to estimate accurately the accounts receivable allowances and ensure that payments are received on a timely basis could have a material adverse effect on Juniper’s business, financial condition, and results of operations. Juniper collects value added tax from its customers for revenues generated out of the United Kingdom for which the customer is not tax exempt and remits such taxes to the appropriate governmental authorities. Juniper presents its value added tax on a net basis; therefore, these taxes are excluded from revenues. Deferred Revenue The Company’s deferred revenue balance consists of the following at December 31, 2017 and 2016 (in thousands): As of December 31, 2017 2016 Product revenues $ 5,888 $ 4,647 Service revenues 253 385 Regional Growth Fund — 592 Total $ 6,141 $ 5,624 Amounts invoiced but not yet earned on product revenues are recorded as deferred revenue until the Company receives sell through information from Merck KGaA indicating the product has been sold through or otherwise disposed of. Amounts invoiced but not yet earned on service revenue are deferred until such time as performance is rendered or the obligation to perform the service is completed for service revenues. As part of the acquisition of Juniper Pharma Services, Juniper assumed a $2.5 million obligation under a grant arrangement with the Regional Growth Fund on behalf of the Secretary of State for Business, Innovation, and Skills in the United Kingdom. Juniper Pharma Services used this grant to fund the building of its second facility, which includes analytical labs, office space, and a manufacturing facility. As a part of the arrangement, Juniper Pharma Services was required to create and maintain certain full-time equivalent personnel levels through October 2017. The obligation ended in October 1, 2017 and the Company met all compliance requirements thru that date.
Research and Development Costs	Research and Development Costs Research and development consist of consultants, material costs, salaries and other personnel related expenses including stock-based compensation of employees and non-employees primarily engaged in research and development activities and materials used and other overhead expenses incurred. All research and development costs are expensed as incurred. Research and development costs that are paid in advance of performance are capitalized as prepaid expenses until incurred. Clinical trial expenses include expenses associated with clinical research organizations. The invoicing from clinical research organizations for services rendered can lag several months. Juniper accrues the cost of services rendered in connection with clinical research organizations activities based on its estimate of costs incurred. Juniper maintains regular communication with its clinical research organizations to assess the reasonableness of its estimates. In March 2015, the Company entered into an exclusive patent license agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital, pursuant to which Juniper has licensed the exclusive worldwide rights to Massachusetts General Hospital patent rights in a novel IVR technology for delivery of one or more pharmaceutical dosages and release rates in a single segmented ring. The Company is leveraging the technology to advance its IVR product candidates: JNP-0101, JNP-0201 and JNP-0301. In August 2016, the Company announced that the Phase 2b clinical trial evaluating COL-1077, 10% lidocaine bioadhesive vaginal gel, for the reduction of pain intensity in women undergoing an endometrial biopsy with tenaculum placement did not achieve its primary and secondary endpoints. The safety and pharmacokinetic (PK) profiles of COL-1077 were consistent with what has been observed in prior clinical trials of the lidocaine bioadhesive vaginal gel. Based on this study outcome the Company discontinued further development of COL-1077, with resources reallocated to its preclinical programs. In September 2017, the Company announced a reduction of approximately 8% of our workforce, primarily in the areas of new product research and development, in order to focus its resources on its core businesses. In addition, as part of its more focused research and development strategy, the Company completed its in vivo in vivo
Stock-based compensation	Stock-based compensation Under the Company’s stock-based compensation program, the Company periodically grants stock options and restricted stock to employees, directors and nonemployee consultants. The fair value of all awards is recognized in the Company’s statement of operations over the requisite service period for each award. Juniper follows the fair value recognition provisions of ASC 718, Stock Compensation Topic Equity – Equity Based Payments to Nonemployees Awards that vest as the recipient provides service are expensed on a straight-line basis over the requisite service period. Other awards, such as performance-based awards that vest upon the achievement of specified goals, are expensed if achievement of the specified goal is considered probable. The Company uses the Black-Scholes option pricing model to value its stock option awards which requires the Company make certain assumptions regarding the expected volatility of its common stock price, the expected term of the option grants, the risk-free interest rate and the dividend yield with respect to its common stock. Due to the lack of the Company’s own historical data, the Company elected to use the simplified method for “plain vanilla” options to estimate the expected term of the Company’s stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. The risk-free interest rate used for each grant is based on the U.S. Treasury yield curve in effect at the time of the grant for instruments with a similar expected life. The Company utilizes a dividend yield of zero based on the fact that the Company has no present intention to pay cash dividends. The Company did not consider any forfeiture rate assumption in its determination of stock-based compensation. The fair value of equity-classified awards to employees and directors are measured at fair value on the grant on the date the awards are granted. Awards to nonemployee consults are recorded at the grant date fair values and are re-measured at each balance sheet date until the recipient’s services are complete. During the years ended December 31, 2017, 2016 and 2015, the Company recorded the following stock-based compensation expense (in thousands): Years Ended December 31, 2017 2016 2015 Cost of revenues $ 120 $ 199 $ 79 Sales and marketing 47 50 38 Research and development 16 73 1,126 General and administrative 1,286 879 507 Total stock-based compensation $ 1,469 $ 1,201 $ 1,750 Stock-based compensation expense is allocated based upon the department of the employee to whom each award was granted. Expenses recognized in connected with the modification of awards in connection with the Company’s strategic restructuring are allocated to restructuring expense. No related tax benefit of the stock-based compensation expense has been recognized. As of December 31, 2017, total unamortized share-based compensation cost related to non-vested stock options and restricted stock was $2.5 million, which is expected to be recognized on a straight-line basis over a weighted average period of 2.7 years.
Net (Loss) Income Per Common Share	Net (Loss) Income Per Common Share The calculation of basic and diluted (loss) income per common and common equivalent share is as follows (in thousands except for per share data): Years Ended December 31, 2017 2016 2015 Basic net (loss) income per common share Net (loss) income $ (2,060 ) $ 5,951 $ (1,496 ) Add: Excess of carrying value of Series C Preferred Stock over redemption value 459 — — Less: Preferred stock dividends (14 ) (28 ) (28 ) Net (loss) income applicable to common stockholders $ (1,615 ) $ 5,923 $ (1,524 ) Basic weighted average number of common shares outstanding 10,824 10,795 10,774 Basic net (loss) income per common share $ (0.15 ) $ 0.55 $ (0.14 ) Diluted net (loss) income per common share Net (loss) income applicable to common stock $ (1,615 ) $ 5,923 $ (1,524 ) Add: Preferred stock dividends — 28 — Net (loss) income applicable to dilutive common stock $ (1,615 ) $ 5,951 $ (1,524 ) Basic weighted average number of common shares outstanding 10,824 10,795 10,774 Effect of dilutive securities Dilutive preferred share conversions — 83 — Dilutive stock awards — 13 — — 96 — Diluted weighted average number of common shares outstanding 10,824 10,891 10,774 Diluted net (loss) income per common share $ (0.15 ) $ 0.55 $ (0.14 ) Basic net (loss) income per common share is computed by dividing the net (loss) income, less preferred dividends and adding the excess of carrying value of Series C Preferred Stock over redemption value recognized on the conversion of the Series C Preferred Stock, by the weighted-average number of shares of common stock outstanding during a period. The diluted net (loss) income per common share calculation gives effect to dilutive options, convertible preferred stock, and other potential dilutive common stock including selected restricted shares of common stock outstanding during the period. Diluted net (loss) income per common share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options, assuming the exercise of all in-the-money stock options. Common share equivalents have been excluded where their inclusion would be anti-dilutive. Shares to be issued upon the exercise of the outstanding options, convertible preferred stock and selected restricted shares of common stock excluded from the income per share calculation amounted to 1,981,934, 1,658,234 and 1,087,308 for the years ended December 31, 2017, 2016 and 2015, respectively, because the awards were anti-dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Adopted In March 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory To be adopted In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment . The standard simplifies the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. The ASU is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, and should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of this standard will not have an impact on our consolidated financial statements and related disclosures. In August 2016, the FASB issued ASU No. 2016-16, Classification of Certain Cash Receipts and Cash Payments , (“ASU 2016-16”), which amends the guidance of ASC No. 230 on the classification of certain items in the statement of cash flows. The primary purpose of ASU 2016-15 is to reduce the diversity in practice by making amendments that add or clarify the guidance on eight specific cash flow issues. ASU 2016-15 is effective for all fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. ASU 2016-15 should be applied retrospectively to all periods presented, but may be applied prospectively from the earliest practicable if retrospective application would be impracticable. The adoption of this standard will not have an impact on our consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the method and impact that the adoption will have on its consolidated financial statements and related disclosures. In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Recognition and Measurement of Financial Assets and Financial Liabilities The adoption of this standard will not have an impact on our consolidated financial statements and related disclosures. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue Recognition Revenue Recognition-Construction-Type and Production-Type Contracts Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net) , Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Inventories	Components of inventory cost include materials, labor and manufacturing overhead. Inventories consist of the following (in thousands): December 31, 2017 2016 Raw materials $ 1,921 $ 856 Work in process 3,299 3,806 Finished goods 1,106 959 Total $ 6,326 $ 5,621
Summary of Accounts Receivable Allowance Activity	Accounts receivable allowance activity consisted of the following for the years ended December 31 (in thousands): 2017 2016 2015 Balance at beginning of year $ 37 $ 263 $ 358 Additions 78 — — Deductions — (226 ) (95 ) Balance at end of year $ 115 $ 37 $ 263
Schedule of Useful Lives of Property and Equipment	Depreciation is computed on the straight-line basis over the estimated useful lives of the respective assets, as follows: Years Machinery and equipment 3-10 Furniture and fixtures 3-5 Computer equipment and software 3-5 Buildings Up to 39 Land Indefinite
Schedule of Accumulated Other Comprehensive Loss	Changes to accumulated other comprehensive loss during the year ended December 31, 2017 were as follows (in thousands): Translation Adjustment Balance – December 31, 2016 $ (5,028 ) Current period other comprehensive income (1,871 ) Balance – December 31, 2017 $ (3,157 )
Schedule of Deferred Revenue Balance	The Company’s deferred revenue balance consists of the following at December 31, 2017 and 2016 (in thousands): As of December 31, 2017 2016 Product revenues $ 5,888 $ 4,647 Service revenues 253 385 Regional Growth Fund — 592 Total $ 6,141 $ 5,624
Schedule of Stock-Based Compensation Expense Allocation	During the years ended December 31, 2017, 2016 and 2015, the Company recorded the following stock-based compensation expense (in thousands): Years Ended December 31, 2017 2016 2015 Cost of revenues $ 120 $ 199 $ 79 Sales and marketing 47 50 38 Research and development 16 73 1,126 General and administrative 1,286 879 507 Total stock-based compensation $ 1,469 $ 1,201 $ 1,750
Assumptions Used to Value Options Granted	Years Ended December 31, 2017 2016 2015 Risk free interest rate 1.45%-1.59% 0.85%-1.45% 0.87%-1.20% Expected term 4.5-4.75 years 4.75 years 4.56-4.75 years Dividend yield — — — Expected volatility 53.15%-55.20% 55.23%-79.29% 76.86%-83.09%
Calculation of Basic and Diluted (Loss) Income Per Common Share and Common Share Equivalents	The calculation of basic and diluted (loss) income per common and common equivalent share is as follows (in thousands except for per share data): Years Ended December 31, 2017 2016 2015 Basic net (loss) income per common share Net (loss) income $ (2,060 ) $ 5,951 $ (1,496 ) Add: Excess of carrying value of Series C Preferred Stock over redemption value 459 — — Less: Preferred stock dividends (14 ) (28 ) (28 ) Net (loss) income applicable to common stockholders $ (1,615 ) $ 5,923 $ (1,524 ) Basic weighted average number of common shares outstanding 10,824 10,795 10,774 Basic net (loss) income per common share $ (0.15 ) $ 0.55 $ (0.14 ) Diluted net (loss) income per common share Net (loss) income applicable to common stock $ (1,615 ) $ 5,923 $ (1,524 ) Add: Preferred stock dividends — 28 — Net (loss) income applicable to dilutive common stock $ (1,615 ) $ 5,951 $ (1,524 ) Basic weighted average number of common shares outstanding 10,824 10,795 10,774 Effect of dilutive securities Dilutive preferred share conversions — 83 — Dilutive stock awards — 13 — — 96 — Diluted weighted average number of common shares outstanding 10,824 10,891 10,774 Diluted net (loss) income per common share $ (0.15 ) $ 0.55 $ (0.14 )

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Changes to Goodwill	Changes to goodwill during the years ended December 31, 2017 and 2016 were as follows (in thousands): Total Balance – December 31, 2015 $ 10,010 Translation adjustment (1,668 ) Balance – December 31, 2016 8,342 Translation adjustment 781 Balance – December 31, 2017 $ 9,123
Changes to Intangible Assets	Intangible assets consist of the following at December 31, 2017 and December 31, 2016 (in thousands): Trademark Developed Technology Customer Relationships Total Gross carrying amount – December 31, 2017 $ 300 $ 1,370 $ 1,240 $ 2,910 Translation adjustment (53 ) (198 ) (179 ) (430 ) Accumulated amortization (247 ) (839 ) (650 ) (1,736 ) Balance – December 31, 2017 $ — $ 333 $ 411 $ 744 Trademark Developed Technology Customer Relationships Total Gross carrying amount – December 31, 2016 $ 300 $ 1,370 $ 1,240 $ 2,910 Translation adjustment (53 ) (298 ) (270 ) (621 ) Accumulated amortization (247 ) (617 ) (456 ) (1,320 ) Balance – December 31, 2016 $ — $ 455 $ 514 $ 969
Amortization Expense on Existing Intangible Assets for Next Four Years	As of December 31, 2017, amortization expense on existing intangible assets for the next four years is as follows (in thousands): Year Total 2018 $ 289 2019 262 2020 193 Total $ 744

Debt and other Contractual Ob24

Debt and other Contractual Obligations (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Summary of Future Contractual Obligations	The Company’s future contractual obligations as of December 31, 2017 include the following (in thousands): Total 2018 2019 2020 2021 2022 Thereafter Operating lease obligations $ 517 $ 443 $ 74 $ — $ — $ — $ — Loan principal repayments 2,422 236 241 248 255 263 1,179 Capital lease obligations 1,377 311 324 338 351 53 — Minimum purchase obligation 5,720 3,861 1,859 — — — — Total $ 10,036 $ 4,851 $ 2,498 $ 586 $ 606 $ 316 $ 1,179

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following (dollars in thousands): Estimated Useful Life December 31, (Years) 2017 2016 Machinery and equipment 3-10 $ 12,358 $ 8,628 Furniture and fixtures 3-5 1,083 1,190 Computer equipment and software 3-5 628 538 Buildings Up to 39 7,995 7,310 Land Indefinite 513 469 Construction in-process 1,133 1,567 23,710 19,702 Less: Accumulated depreciation (8,481 ) (6,336 ) Total $ 15,229 $ 13,366

Accrued Expenses and Other (Tab

Accrued Expenses and Other (Tables)	12 Months Ended
	Dec. 31, 2017
Payables And Accruals [Abstract]
Schedule of Accrued Expenses and Other	Accrued expenses and other consist of the following (in thousands): December 31, 2017 2016 Payroll $ 1,795 $ 1,643 Professional fees 2,006 1,074 Clinical studies 204 740 Other 1,361 1,814 Restructuring 249 - Total $ 5,615 $ 5,271

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Domestic and Foreign (Loss) Income, Before Income Taxes	(Loss) income before income taxes consists of the following (in thousands): Year Ended December 31, 2017 2016 2015 Domestic $ (15,887 ) $ (2,090 ) $ (8,133 ) Foreign 13,641 8,132 6,642 (Loss) income before income taxes $ (2,246 ) $ 6,042 $ (1,491 )
Components of the (Benefit) Provision for Income Taxes	The components of the (benefit) provision for income taxes are as follows (in thousands): Year Ended December 31, 2017 2016 2015 Current: Federal $ (46 ) $ 80 $ (9 ) State — 11 14 Foreign — — — Total current (46 ) 91 5 Deferred: Foreign (140 ) — — Total deferred (140 ) — — (Benefit) provision for income taxes $ (186 ) $ 91 $ 5
Reconciliation of the Federal Statutory Rate to Effective Tax Rate	The reconciliation of the federal statutory rate to Juniper’s effective tax rate is as follows: Year Ended December 31, 2017 2016 2015 Federal income tax rate 34.0 % 34.0 % 34.0 % Foreign rate differential 182.7 % (49.6 )% 151.5 % State tax, net of federal benefit 10.1 13.4 (0.9 ) Permanent Items: Incentive stock options (2.5 ) 1.0 (14.9 ) Dividend from foreign subsidiary (165.8 ) 53.5 (79.8 ) Amortization of technical rights — (34.5 ) 23.4 Deferred adjustments 15.9 30.6 6.6 Foreign research and development relief 26.3 — — Change in U.S. Federal rate (970.4 ) — — Other (2.6 ) (1.1 ) (0.5 ) Effect of permanent differences (1,099.1 ) 49.5 (65.2 ) Effective income tax rate (872.3 ) 47.3 119.4 Change in valuation allowance 880.6 (45.8 ) (119.7 ) Effective income tax rate 8.3 % 1.5 % (0.3 )%
Components of Net Deferred Tax Assets and Liabilities	The components of the Company’s net deferred tax assets and liabilities are as follows (in thousands): December 31, 2017 December 31, 2016 Deferred Tax Asset Net Operating Loss $ 37,168 $ 55,521 Tax Credits 1,846 2,034 Stock Based Compensation 900 997 Intangibles 489 843 Other 290 337 Subtotal 40,693 59,732 Less: Valuation Allowance (39,072 ) (58,983 ) Total Deferred Tax Assets 1,621 749 Deferred Tax Liabilities Fixed Assets (1,621 ) (749 ) Total Deferred Tax Liabilities (1,621 ) (749 ) Net Deferred Tax Asset $ — $ —

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Summary of Company's Stock Option Plans	A following table summarizes stock option activity during the year ended December 31, 2017: Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (year) Aggregate Intrinsic Value (in thousands) Outstanding, December 31, 2016 1,516,059 $ 7.25 5.19 $ 48 Granted 680,400 5.17 Exercised — — Forfeited (394,409 ) 6.71 Outstanding, December 31, 2017 1,802,050 $ 6.59 4.86 $ 8 Vested 822,736 7.19 3.85 — Unvested 979,314 6.08 5.71 8 Vested or expected to vest, December 31, 2017 1,802,050 $ 6.59 4.86 $ 8 Exercisable, December 31, 2017 822,736 $ 7.19 3.85
Assumptions Used to Value Options Granted	Years Ended December 31, 2017 2016 2015 Risk free interest rate 1.45%-1.59% 0.85%-1.45% 0.87%-1.20% Expected term 4.5-4.75 years 4.75 years 4.56-4.75 years Dividend yield — — — Expected volatility 53.15%-55.20% 55.23%-79.29% 76.86%-83.09%
Summary of Company's Restricted Stock Activity and Related Information	A summary of the Company’s restricted stock activity and related information for the year ended December 31, 2017 is as follows: Shares Weighted Average Grant Date Fair Value Unvested, December 31, 2016 40,933 $ 7.42 Granted 118,934 $ 5.03 Vested (40,933 ) $ 7.42 Forfeited (15,500 ) $ 5.15 Unvested, December 31, 2017 103,434 $ 5.01
Performance-Based Restricted Stock Units [Member]
Summary of Company's Restricted Stock Activity and Related Information	A summary of the Company’s performance-based restricted stock activity for the year ended December 31, 2017 is as follows: Performance-based Restricted Stock Units Unvested, December 31, 2016 — Granted 186,000 Vested — Forfeited (109,550 ) Unvested, December 31, 2017 76,450
Employees [Member]
Assumptions Used to Value Options Granted	The weighted-average fair value of the options granted to employees during the years ended December 31, 2017, 2016 and 2015 was $2.43, $4.66 and $4.38, respectively based on the following assumptions: Years Ended December 31, 2017 2016 2015 Risk free interest rate 1.45%-1.59% 0.85%-1.45% 0.87%-1.20% Expected term 4.5-4.75 years 4.75 years 4.56-4.75 years Dividend yield — — — Expected volatility 53.15%-55.20% 55.23%-79.29% 76.86%-83.09%
Non-Employees [Member]
Assumptions Used to Value Options Granted	The weighted-average fair value of the options granted to non-employees during the year ended December 31, 2015 was $4.52 based on the following assumptions: 2015 Risk free interest rate 1.47%-1.54% Expected term 7 years Dividend yield — Expected volatility 82.88%-83.09%

Segments and Geographic Infor29

Segments and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Selected Information by Geographic Area	The following tables show selected information by geographic area (in thousands): Revenues: Year Ended December 31, 2017 2016 2015 United States $ 10,464 $ 19,955 $ 7,677 Switzerland 33,264 27,302 23,139 United Kingdom 3,559 4,632 4,422 Other countries 2,692 2,684 3,049 Subtotal international 39,515 34,618 30,610 Total $ 49,979 $ 54,573 $ 38,287 Total assets: December 31, 2017 2016 United States $ 21,683 $ 21,423 Switzerland 1,366 4,673 United Kingdom 38,129 31,288 Other countries 42 187 Total $ 61,220 $ 57,571 Long-lived assets: December 31, 2017 2016 United States $ 523 $ 663 Switzerland 535 369 United Kingdom 15,064 13,468 Other countries 2 2 Total $ 16,124 $ 14,502
Schedule of Other Information by Segment	The following summarizes other information by segment for the year ended December 31, 2017 (in thousands): Product Service Total Revenues Product revenues $ 32,688 $ — $ 32,688 Service revenues — 17,291 17,291 Total revenues 32,688 17,291 49,979 Cost of product revenues 19,013 — 19,013 Cost of service revenues — 9,948 9,948 Total cost of revenues 19,013 9,948 28,961 Gross profit $ 13,675 $ 7,343 $ 21,018 Total operating expenses 24,881 Total non-operating income 1,617 Income before income taxes $ (2,246 ) The following summarizes other information by segment for the year ended December 31, 2016 (in thousands): Product Service Total Revenues Product revenues $ 27,211 $ — $ 27,211 Service revenues — 13,065 13,065 Royalties 14,297 — 14,297 Total revenues 41,508 13,065 54,573 Cost of product revenues 15,595 — 15,595 Cost of service revenues — 8,698 8,698 Total cost of revenues 15,595 8,698 24,293 Gross profit $ 25,913 $ 4,367 $ 30,280 Total operating expenses 25,001 Total non-operating income 763 Loss before income taxes $ 6,042 The following summarizes other information by segment for the year ended December 31, 2015 (in thousands): Product Service Total Revenues Product revenues $ 22,891 $ — $ 22,891 Service revenues — 11,651 11,651 Royalties 3,745 — 3,745 Total revenues 26,636 11,651 38,287 Cost of product revenues 13,053 — 13,053 Cost of service revenues — 8,361 8,361 Total cost of revenues 13,053 8,361 21,414 Gross profit $ 13,583 $ 3,290 $ 16,873 Total operating expenses 18,746 Total non-operating income 382 Income before income taxes $ (1,491 )
Schedule of Revenue by Customer	The following table presents information about Juniper’s revenues by customer, including product sales, royalty and license revenue and service revenues for each customer accounting for 10% or more of consolidated revenues in any of the three years ended December 31 by segment: Product Year Ended December 31, 2017 2016 2015 Merck KGaA 100 % 66 % 86 % Allergan - 34 14 Total 100 % 100 % 100 %

Quarterly Financial Informati30

Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Summary of Selected Quarterly Data	The following table sets forth specific unaudited consolidated quarterly statement of operations data for the eight quarters ended December 31, 2017 (in thousands). This information is unaudited, but in the opinion of management, it has been prepared on the same basis as the audited consolidated financial statements and all necessary adjustments, consisting only of normal recurring adjustments, have been included in the amounts stated below to state fairly the unaudited consolidated quarterly results of operations. The results of operations for any quarter are not necessarily indicative of the results of operations for any future period. First Quarter Second Quarter Third Quarter Fourth Quarter 2017 Revenues $ 11,247 $ 13,956 $ 12,986 $ 11,790 Gross profit 4,691 6,306 5,267 4,754 Operating expenses 6,146 6,662 6,802 5,271 (Loss) income from operations (1,455 ) (356 ) (1,535 ) (517 ) Net (loss) income (1,441 ) (376 ) (1,410 ) 1,167 (Loss) income per common share: Basic $ (0.13 ) $ 0.01 $ (0.13 ) $ 0.11 Diluted $ (0.13 ) $ (0.03 ) $ (0.13 ) $ 0.11 First Quarter Second Quarter Third Quarter Fourth Quarter 2016 Revenues $ 10,477 $ 11,610 $ 11,556 $ 20,930 Gross profit 4,127 5,143 5,851 15,159 Operating expenses 5,865 7,420 5,674 6,042 (Loss) income from operations (1,738 ) (2,277 ) 177 9,117 Net (loss) income (1,643 ) (2,268 ) 248 9,614 (Loss) income per common share: Basic $ (0.15 ) $ (0.21 ) $ 0.02 $ 0.89 Diluted $ (0.15 ) $ (0.21 ) $ 0.02 $ 0.88

Restructuring Charges (Tables)

Restructuring Charges (Tables)	12 Months Ended
	Dec. 31, 2017
Restructuring And Related Activities [Abstract]
Summary of Components of Restructuring Activity	The following table summarizes the components of the Company’s restructuring activity recorded in the accompanying balance sheet (in thousands): Amounts accrued at December 31, 2016 Expense incurred during the year ended December 31, 2017 Amounts paid during the year ended December 31, 2017 Amounts accrued at December 31, 2017 Employee severance, benefits and related costs $ — $ 412 $ (340 ) $ 72 Obligations under manufacturing and development contracts — 296 (13 ) 283 $ — $ 708 $ (353 ) $ 355

Organization - Additional Infor

Organization - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Cash and cash equivalents	$ 21,446	$ 20,994	$ 13,901	$ 16,762

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Additional Information (Detail)	1 Months Ended					12 Months Ended
	Jan. 31, 2018	Sep. 30, 2017	Nov. 30, 2016USD ($)	Sep. 30, 2013USD ($)	Apr. 30, 2013	Dec. 31, 2017USD ($)SegmentCustomershares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares	Jan. 01, 2018USD ($)
Schedule Of Significant Accounting Policies [Line Items]
Number of operating segments | Segment						2
Number of reporting segments | Segment						2
Foreign currency re-measurement losses						$ 600,000	$ 200,000	$ 70,000
Financial assets level 1 to level 2 transfers amount						0
Financial assets level 2 to level 1 transfers amount						0
Reserves for excess and obsolete inventory						500,000	45,000
Charges for excess and obsolete inventory						400,000	0
Net of allowance for doubtful accounts						4,734,000	6,573,000
Unbilled accounts receivable						$ 3,000,000	1,300,000
Number of major customers | Customer						1
Number of reporting unit | Customer						2
Goodwill impaired						$ 0
Valuation allowance						39,072,000	58,983,000
Reclassification from accumulated other comprehensive loss to net (loss) income						$ 0
One time payment, royalty revenues							14,297,000	$ 3,745,000
Dividend yield						0.00%
Tax benefit from stock-based compensation expense recognized						$ 0	$ 0
Unamortized share-based compensation cost related to non-vested stock options and restricted stock not yet recognized						$ 300,000
Weighted average period to recognize unamortized share-based compensation cost related to non-vested stock options and restricted stock						2 years 1 month 6 days
Antidilutive securities excluded from computation of earnings per share | shares						1,981,934	1,658,234	1,087,308
Employee Stock Option [Member]
Schedule Of Significant Accounting Policies [Line Items]
Unamortized share-based compensation cost related to non-vested stock options and restricted stock not yet recognized						$ 2,500,000
Weighted average period to recognize unamortized share-based compensation cost related to non-vested stock options and restricted stock						2 years 8 months 12 days
Research and Development [Member]
Schedule Of Significant Accounting Policies [Line Items]
Percentage of reduction in workforce		8.00%
Juniper Pharma Services [Member]
Schedule Of Significant Accounting Policies [Line Items]
Assumed obligation under grant arrangement by the entity				$ 3,900,000
Juniper Pharma Services [Member] | Regional Growth Fund [Member]
Schedule Of Significant Accounting Policies [Line Items]
Assumed obligation under grant arrangement by the entity				$ 2,500,000		$ 2,500,000
Allergan [Member]
Schedule Of Significant Accounting Policies [Line Items]
One time payment, royalty revenues			$ 11,000,000
Subsequent Event [Member] | Accounting Standards Update No. 2014-09 [Member]
Schedule Of Significant Accounting Policies [Line Items]
Cumulative adjustment to increase retained earnings									$ 5,700,000
Merck KGaA [Member]
Schedule Of Significant Accounting Policies [Line Items]
Additional license and supply agreement renewals term					5 years
License and supply agreement expiration date					May 19, 2020
Merck KGaA [Member] | Subsequent Event [Member]
Schedule Of Significant Accounting Policies [Line Items]
License and supply agreement expiration date	Dec. 31, 2024
Extension term of the supply agreement	4 years 6 months
Minimum [Member]
Schedule Of Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life						3 years
Minimum [Member] | Merck KGaA [Member]
Schedule Of Significant Accounting Policies [Line Items]
Revenue recognition, recorded revenue cost plus percentage						20.00%
Maximum [Member]
Schedule Of Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life						7 years

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory Net Items Net Of Reserve Alternative [Abstract]
Raw materials	$ 1,921	$ 856
Work in process	3,299	3,806
Finished goods	1,106	959
Total	$ 6,326	$ 5,621

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Summary of Accounts Receivable Allowance Activity (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Balance at beginning of year	$ 37	$ 263	$ 358
Additions	78
Deductions		(226)	(95)
Balance at end of year	$ 115	$ 37	$ 263

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2017
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	5 years
Computer Equipment and Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Computer Equipment and Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	5 years
Buildings [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	39 years
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	Indefinite

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Schedule of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ 39,770	$ 36,512	$ 37,325
Current period other comprehensive income	1,871	(3,866)	(1,099)
Ending balance	41,512	39,770	$ 36,512
Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(5,028)
Current period other comprehensive income	(1,871)
Ending balance	$ (3,157)	$ (5,028)

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Schedule of Deferred Revenue Balance (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 6,141	$ 5,624
Product Revenues [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	5,888	4,647
Service Revenues [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 253	385
Regional Growth Fund [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue		$ 592

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Schedule of Stock-Based Compensation Expense Allocation (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 1,469	$ 1,201	$ 1,750
Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	120	199	79
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	47	50	38
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	16	73	1,126
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 1,286	$ 879	$ 507

Summary of Significant Accoun40

Summary of Significant Accounting Policies - Assumptions Used to Value Options Granted (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		4 years 9 months
Dividend yield	0.00%	0.00%	0.00%
Minimum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.45%	0.85%	0.87%
Expected term	4 years 6 months		4 years 6 months 21 days
Expected volatility	53.15%	55.23%	76.86%
Maximum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.59%	1.45%	1.20%
Expected term	4 years 9 months		4 years 9 months
Expected volatility	55.20%	79.29%	83.09%

Summary of Significant Accoun41

Summary of Significant Accounting Policies - Calculation of Basic and Diluted (Loss) Income Per Common Share and Common Share Equivalents (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Basic net (loss) income per common share
Net (loss) income	$ 1,167	$ (1,410)	$ (376)	$ (1,441)	$ 9,614	$ 248	$ (2,268)	$ (1,643)	$ (2,060)	$ 5,951	$ (1,496)
Less: Preferred stock dividends									(14)	(28)	(28)
Net (loss) income available to common stockholders									$ (1,615)	$ 5,923	$ (1,524)
Basic weighted average common shares outstanding									10,824	10,795	10,774
Basic net (loss) income per common share	$ 0.11	$ (0.13)	$ 0.01	$ (0.13)	$ 0.89	$ 0.02	$ (0.21)	$ (0.15)	$ (0.15)	$ 0.55	$ (0.14)
Diluted net (loss) income per common share
Net (loss) income applicable to common stock									$ (1,615)	$ 5,923	$ (1,524)
Add: Preferred stock dividends									14	28	28
Net (loss) income applicable to dilutive common stock									$ (1,615)	$ 5,951	$ (1,524)
Basic weighted average common shares outstanding									10,824	10,795	10,774
Effect of dilutive securities
Dilutive preferred share conversions										83
Dilutive stock awards										13
Weighted average number of diluted shares outstanding adjustment										96
Diluted weighted average number of common shares outstanding									10,824	10,891	10,774
Diluted net (loss) income per common share	$ 0.11	$ (0.13)	$ (0.03)	$ (0.13)	$ 0.88	$ 0.02	$ (0.21)	$ (0.15)	$ (0.15)	$ 0.55	$ (0.14)
Series C Preferred Stock [Member]
Basic net (loss) income per common share
Add: Excess of carrying value of Series C Preferred Stock over redemption value									$ 459

Goodwill and Intangible Asset42

Goodwill and Intangible Assets - Schedule of Changes to Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Beginning balance	$ 8,342	$ 10,010
Translation adjustment	781	(1,668)
Ending balance	$ 9,123	$ 8,342

Goodwill and Intangible Asset43

Goodwill and Intangible Assets - Changes to Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,910	$ 2,910
Translation adjustment	(430)	(621)
Accumulated amortization	(1,736)	(1,320)
Balance	744	969
Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	300	300
Translation adjustment	(53)	(53)
Accumulated amortization	(247)	(247)
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,370	1,370
Translation adjustment	(198)	(298)
Accumulated amortization	(839)	(617)
Balance	333	455
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,240	1,240
Translation adjustment	(179)	(270)
Accumulated amortization	(650)	(456)
Balance	$ 411	$ 514

Goodwill and Intangible Asset44

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Acquired Finite-Lived Intangible Assets [Line Items]
Impairment of long-lived assets	$ 0
Estimated useful life of the acquired intangible assets	6 years 7 months 6 days
Amortization expense	$ 300,000	$ 400,000	$ 400,000
Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life of the acquired intangible assets	3 years
Developed Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life of the acquired intangible assets	7 years
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life of the acquired intangible assets	7 years

Goodwill and Intangible Asset45

Goodwill and Intangible Assets - Amortization Expense on Existing Intangible Assets for Next Four Years (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2,018	$ 289
2,019	262
2,020	193
Total	$ 744	$ 969

Debt and Other Contractual Ob46

Debt and Other Contractual Obligations - Additional Information (Detail)	1 Months Ended				12 Months Ended
	May 31, 2017Facility	Mar. 31, 2017USD ($)	Jan. 31, 2017USD ($)	Sep. 30, 2013USD ($)	Dec. 31, 2017USD ($)FacilityLoan	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Debt Instrument [Line Items]
Amount owe under loan facility					$ 2,422,000
Lease agreement term					39 months
Lease agreement, expiration year					2,019
Lease agreement rent free period					3 months
Capital lease term					60 months
Proceeds from equipment loans					$ 1,501,000
Rent Expense					400,000	$ 400,000	$ 300,000
Interest expense, net					$ 100,000	100,000	100,000
Loan for Equipment [Member] | Nottingham, UK Facility [Member]
Debt Instrument [Line Items]
Number of loans | Loan					2
Loans payment maturity month and year					2022-03
Loan for Equipment [Member] | Loan One [Member] | Nottingham, UK Facility [Member]
Debt Instrument [Line Items]
Proceeds from equipment loans			$ 900,000
Interest rates at the end of period					2.09%
Loan for Equipment [Member] | Loan Two [Member] | Nottingham, UK Facility [Member]
Debt Instrument [Line Items]
Proceeds from equipment loans		$ 600,000
Interest rates at the end of period					2.09%
Juniper Pharma Services [Member]
Debt Instrument [Line Items]
Debt assumed				$ 3,900,000
Number of loan facilities | Facility					3
Number of loan facilities repaid | Facility	1
Gain loss on refinancing of debt					$ 0
Amount owe under loan facility					$ 2,400,000
Weighted average interest rate for the period					2.76%
Juniper Pharma Services [Member] | Regional Growth Fund [Member]
Debt Instrument [Line Items]
Debt assumed				$ 2,500,000	$ 2,500,000
Obligation under a grant arrangement, maturity date				Oct. 1, 2017
Other income					$ 600,000	$ 700,000	$ 500,000
Term of agreement over which income was recognized					3 years
Juniper Pharma Services [Member] | Minimum [Member]
Debt Instrument [Line Items]
Loan facilities repayment period					7 years
Juniper Pharma Services [Member] | Maximum [Member]
Debt Instrument [Line Items]
Loan facilities repayment period					15 years
Juniper Pharma Services [Member] | Loan Facility One [Member]
Debt Instrument [Line Items]
Loan repayment commencement period					2013-02
Loan facilities bear interest rate					1.95%
Loan facility interest rate description					base rate plus 1.95%
Weighted average interest rate at the end of period					2.45%
Juniper Pharma Services [Member] | Loan Facility Two [Member]
Debt Instrument [Line Items]
Loan repayment commencement period					2013-10
Loan facilities bear interest rate					2.55%
Loan facility interest rate description					base rate plus 2.55%
Weighted average interest rate at the end of period					3.05%
Juniper Pharma Services [Member] | Loan Facility Three [Member]
Debt Instrument [Line Items]
Loan repayment commencement period					2013-10
Loan facilities bear interest rate					2.99%

Debt and Other Contractual Ob47

Debt and Other Contractual Obligations - Summary of Future Contractual Obligations (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Debt Disclosure [Abstract]
Operating lease obligations, Total	$ 517
Operating lease obligations, 2018	443
Operating lease obligations, 2019	74
Loan principal repayments, Total	2,422
Loan principal repayments, 2018	236
Loan principal repayments, 2019	241
Loan principal repayments, 2020	248
Loan principal repayments, 2021	255
Loan principal repayments, 2022	263
Loan principal repayments, Thereafter	1,179
Capital lease obligations, Total	1,377
Capital lease obligations, 2018	311
Capital lease obligations, 2019	324
Capital lease obligations, 2020	338
Capital lease obligations, 2021	351
Capital lease obligations, 2022	53
Minimum purchase obligation, Total	5,720
Minimum purchase obligation, 2018	3,861
Minimum purchase obligation, 2019	1,859
Total	10,036,000
2,018	4,851,000
2,019	2,498,000
2,020	586,000
2,021	606,000
2,022	316,000
Thereafter	$ 1,179,000

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 23,710	$ 19,702
Less: Accumulated depreciation	(8,481)	(6,336)
Total	15,229	13,366
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 12,358	8,628
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	10 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 1,083	1,190
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	5 years
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 628	538
Computer Equipment and Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Computer Equipment and Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	5 years
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 7,995	7,310
Buildings [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	39 years
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 513	469
Property, plant and equipment useful life (in years)	Indefinite
Construction in-Process [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 1,133	$ 1,567

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Depreciation [Abstract]
Depreciation expense	$ 1.9	$ 1.5	$ 1.5
Book value of property and equipment under debt agreement	$ 7.4	$ 5.5

Accrued Expenses and Other - Sc

Accrued Expenses and Other - Schedule of Accrued Expenses and Other (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Payroll	$ 1,795	$ 1,643
Professional fees	2,006	1,074
Clinical studies	204	740
Other	1,361	1,814
Restructuring	249
Total	$ 5,615	$ 5,271

Income Taxes - Schedule of Dome

Income Taxes - Schedule of Domestic and Foreign (Loss) Income, Before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Domestic	$ (15,887)	$ (2,090)	$ (8,133)
Foreign	13,641	8,132	6,642
(Loss) income before income taxes	$ (2,246)	$ 6,042	$ (1,491)

Income Taxes - Components of th

Income Taxes - Components of the (Benefit) Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current:
Federal	$ (46)	$ 80	$ (9)
State	0	11	14
Foreign	0	0	0
Total current	(46)	91	5
Deferred:
Foreign	(140)	0	0
Total deferred	(140)	0	0
(Benefit) provision for income taxes	$ (186)	$ 91	$ 5

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of the Federal Statutory Rate to Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Federal income tax rate	34.00%	34.00%	34.00%
Foreign rate differential	182.70%	(49.60%)	151.50%
State tax, net of federal benefit	10.10%	13.40%	(0.90%)
Permanent Items:
Incentive stock options	(2.50%)	1.00%	(14.90%)
Dividend from foreign subsidiary	(165.80%)	53.50%	(79.80%)
Amortization of technical rights	(0.00%)	(34.50%)	23.40%
Deferred adjustments	15.90%	30.60%	6.60%
Foreign research and development relief	26.30%	0.00%	0.00%
Change in U.S. Federal rate	(970.40%)	0.00%	0.00%
Other	(2.60%)	(1.10%)	(0.50%)
Effect of permanent differences	(1099.10%)	49.50%	(65.20%)
Effective income tax rate	(872.30%)	47.30%	119.40%
Change in valuation allowance	880.60%	(45.80%)	(119.70%)
Effective income tax rate	8.30%	1.50%	(0.30%)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Taxes And Tax Related [Line Items]
Tax benefit attributable to Alternative Minimum Tax credit carryover in connection with the Tax Cuts and Jobs Act of 2017			$ 200,000
Measurement period for record provisional amount			1 year
U.S. corporate income tax rate			34.00%	34.00%	34.00%
Decrease in deferred tax assets			$ 22,000,000
Transition tax inclusion in income			0
Income tax effect in current period			$ 0
Alternative minimum tax credit carryforward refund percentage			50.00%
Valuation allowance			$ 100,000
Current income tax receivable			100,000
Non-current income tax receivable			100,000
Income tax (benefit) expense			$ 200,000
Net interest expense deductible in excess of adjusted taxable income percentage			30.00%
Unrecognized tax benefits, income tax penalties and interest accrued			$ 0	$ 0
Federal [Member]
Income Taxes And Tax Related [Line Items]
Operating tax loss carryforwards, estimated			$ 164,000,000
Operating tax loss carryforwards, estimated expire year			2,020
Research and development tax credit carryforward, amount			$ 1,800,000
Research and development tax credit carryforward, amount expire year			2,018
State and Local Jurisdiction [Member]
Income Taxes And Tax Related [Line Items]
Operating tax loss carryforwards, estimated			$ 20,000,000
Operating tax loss carryforwards, estimated expire year			2,018
U.K. [Member]
Income Taxes And Tax Related [Line Items]
Operating tax loss carryforwards, estimated			$ 11,500,000
Research and development tax credit carryforward, amount			$ 300,000
Minimum [Member]
Income Taxes And Tax Related [Line Items]
Global intangible low taxed income tax rate			10.00%
Earliest Tax Year [Member]
Income Taxes And Tax Related [Line Items]
Open tax year			2,018
Latest Tax Year [Member]
Income Taxes And Tax Related [Line Items]
Open tax year			2,020
Tax Year 2021 [Member]
Income Taxes And Tax Related [Line Items]
Alternative minimum tax credit carryforward refund percentage			100.00%
Scenario, Plan [Member]
Income Taxes And Tax Related [Line Items]
U.S. corporate income tax rate		21.00%
Scenario, Forecast [Member]
Income Taxes And Tax Related [Line Items]
Percentage of limitation on net operating losses of annual income	80.00%

Income Taxes - Components of Ne

Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred Tax Asset
Net Operating Loss	$ 37,168	$ 55,521
Tax Credits	1,846	2,034
Stock Based Compensation	900	997
Intangibles	489	843
Other	290	337
Subtotal	40,693	59,732
Valuation Allowance	(39,072)	(58,983)
Total Deferred Tax Assets	1,621	749
Fixed Assets	(1,621)	(749)
Total Deferred Tax Liabilities	(1,621)	(749)
Net Deferred Tax Asset	$ 0	$ 0

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands	Jun. 30, 2017USD ($)shares	Mar. 31, 2013	Sep. 30, 2011	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016$ / sharesshares	Nov. 30, 2010	Mar. 31, 2002$ / sharesshares
Class of Stock [Line Items]
Common stock, shares authorized				150,000,000	150,000,000
Common stock, par value | $ / shares				$ 0.01	$ 0.01
Common stock, shares issued				12,256,980	12,257,000
Common stock, shares outstanding				10,844,113	10,844,000
Preferred stock, shares authorized				1,000,000	1,000,000
Preferred stock, par value | $ / shares				$ 0.01	$ 0.01
Preferred stock, shares issued				0
Preferred stock, shares outstanding				0
Preferred stock, redemption date				Jun. 30, 2017
Dividends declared, share, preferred stock purchase right for outstanding common stock							1
Exercise Price | $ / shares				$ 0.01
Minimum ownership percentage for change				5.00%
Period for ownership change				3 years
Right plan expiration date		Jul. 3, 2013	Mar. 12, 2012
Right plan extended expiration date		Jul. 3, 2016	Jul. 3, 2013
Conversion Threshold, 15% [Member]
Class of Stock [Line Items]
Preferred stock, conversion trigger, percentage ownership change							15.00%
Conversion Threshold, Greater than 15% and Less than 50% [Member]
Class of Stock [Line Items]
Preferred stock, conversion trigger, percentage ownership change							50.00%
Conversion Threshold, Revised, 4.99% [Member]
Class of Stock [Line Items]
Preferred stock, conversion trigger, percentage ownership change						4.99%
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued				0	130
Preferred stock, shares outstanding				0	130
Each share of preferred stock converted into common stock	2.78
Preferred shares converted into common stock, shares	361
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding				0	550
Payment for redemption of preferred stock | $	$ 10
Amount recorded in excess of carrying value over redemption value | $				$ 459
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, conversion amount, per one thousandth of a share | $ / shares							$ 30

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Detail) - USD ($)	Feb. 07, 2018	Jan. 08, 2018	Mar. 31, 2018	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation expense, shares					66,234	42,203	13,106
Stock options granted					680,400
Cash received from option exercised							$ 82,000
Stock option exercised					0	0
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition					2 years 1 month 6 days
Stock-based compensation expense					$ 1,469,000	$ 1,201,000	$ 1,750,000
Tax benefit from stock-based compensation expense recognized					0	$ 0
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized					300,000
Total fair value of shares vested during the years					$ 300,000
Subsequent Event [Member] | Merck KGaA, Darmstandt [Member] | Germany [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of supply agreement extended		4 years 6 months
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted					680,400	657,500	387,000
Weighted-average grant date fair values of options granted					$ 2.43	$ 4.66	$ 4.38
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted					0	0
Weighted-average grant date fair values of options granted							$ 4.52
Reduction of stock-based compensation expense					$ 100,000	$ 100,000
Stock-based compensation expense							$ 1,100,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred compensation arrangement with individual, maximum contractual term					10 years
Total unrecognized compensation costs related to non-vested options					$ 2,500,000
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition					2 years 8 months 12 days
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized					$ 2,500,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period					2 years
Number of shares, awarded					118,934
Shares, vested					40,933
Restricted Stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period					1 year
Restricted Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period					4 years
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, awarded					186,000	0
Shares, vested					0
Performance-Based Restricted Stock Units [Member] | Board of Director [Member] | Scenario, Forecast [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ 200,000
Performance-Based Restricted Stock Units [Member] | Board of Director [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, vested	27,800
2008 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance								1,250,000
Share-based compensation, vesting percentage								25.00%
Share-based compensation arrangement by share-based payment award, award vesting period					48 months
2015 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance				1,000,000			1,000,000
Share-based compensation, vesting percentage				6.25%			25.00%
Share-based compensation arrangement by share-based payment award, award vesting period					48 months
2015 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance				200,000			200,000
Amended and Restated 2015 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, available for future grant					1,861,142
Prior To 2006 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred compensation arrangement with individual, maximum contractual term					10 years
2006 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred compensation arrangement with individual, maximum contractual term					7 years

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Company's Stock Option Plans (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Options, Outstanding at beginning of year	1,516,059
Number of Options, Granted	680,400
Number of Options, Exercised	0	0
Number of Options, Forfeited	(394,409)
Number of Options, Outstanding at end of year	1,802,050	1,516,059
Number of Options, Vested	822,736
Number of Options, Unvested	979,314
Number of Options, Vested or expected to vest, December 31, 2017	1,802,050
Number of Options, Exercisable, December 31, 2017	822,736
Weighted-Average Exercise Price, Outstanding at beginning of year	$ 7.25
Weighted-Average Exercise Price, Granted	5.17
Weighted-Average Exercise Price, Forfeited	6.71
Weighted-Average Exercise Price, Outstanding at end of year	6.59	$ 7.25
Weighted-Average Exercise Price, Vested	7.19
Weighted-Average Exercise Price, Unvested	6.08
Weighted-Average Exercise Price, Vested or expected to vest, December 31, 2017	6.59
Weighted-Average Exercise Price, Exercisable, December 31, 2017	$ 7.19
Weighted-Average Remaining Contractual Life, Outstanding	4 years 10 months 9 days	5 years 2 months 8 days
Weighted-Average Remaining Contractual Life, Vested	3 years 10 months 6 days
Weighted-Average Remaining Contractual Life, Unvested	5 years 8 months 15 days
Weighted-Average Remaining Contractual Life, Vested or expected to vest, December 31, 2017	4 years 10 months 9 days
Weighted-Average Remaining Contractual Life, Exercisable, December 31, 2017	3 years 10 months 6 days
Aggregate Intrinsic Value, Outstanding	$ 48
Aggregate Intrinsic Value, Outstanding	8	$ 48
Aggregate Intrinsic Value, Unvested	8
Aggregate Intrinsic Value, Vested or expected to vest, December 31, 2017	$ 8

Stock-based Compensation - Assu

Stock-based Compensation - Assumptions Used to Value Options Granted (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		4 years 9 months
Dividend yield	0.00%	0.00%	0.00%
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term			7 years
Dividend yield			0.00%
Minimum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.45%	0.85%	0.87%
Expected term	4 years 6 months		4 years 6 months 21 days
Expected volatility	53.15%	55.23%	76.86%
Minimum [Member] | Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate			1.47%
Expected volatility			82.88%
Maximum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.59%	1.45%	1.20%
Expected term	4 years 9 months		4 years 9 months
Expected volatility	55.20%	79.29%	83.09%
Maximum [Member] | Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate			1.54%
Expected volatility			83.09%

Stock-based Compensation - Su60

Stock-based Compensation - Summary of Company's Restricted Stock Activity and Related Information (Detail) - Restricted Stock [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Unvested at beginning of period | shares	40,933
Shares, Granted | shares	118,934
Shares, Vested | shares	(40,933)
Shares, Forfeited | shares	(15,500)
Shares, Unvested at ending of period | shares	103,434
Weighted Average Grant Date Fair Value, Unvested at beginning of period | $ / shares	$ 7.42
Weighted Average Grant Date Fair Value, Granted | $ / shares	5.03
Weighted Average Grant Date Fair Value, Vested | $ / shares	7.42
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	5.15
Weighted Average Grant Date Fair Value, Unvested at end of period | $ / shares	$ 5.01

Stock-based Compensation - Su61

Stock-based Compensation - Summary of Company's Performance-based Restricted Stock Activity and Related Information (Detail) - Performance-Based Restricted Stock Units [Member] - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Unvested at beginning of period	0
Shares, Granted	186,000	0
Shares, Vested	0
Shares, Forfeited	(109,550)
Shares, Unvested at ending of period	76,450	0

Segments and Geographic Infor62

Segments and Geographic Information - Additional Information (Detail) $ in Thousands	1 Months Ended	12 Months Ended
	Nov. 30, 2016USD ($)	Dec. 31, 2017SegmentCustomer	Dec. 31, 2016USD ($)Customer	Dec. 31, 2015USD ($)Customer
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of operating segments | Segment		2
One time payment, royalty revenues			$ 14,297	$ 3,745
Concentration risk percentage		100.00%	100.00%	100.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Service [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Customers accounted for 10% or more of total revenues | Customer		1	0	0
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Service [Member] | Customer One [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage		33.00%
Credit Concentration Risk | Accounts Receivable [Member] | Service [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of customers | Customer		1	2	1
Credit Concentration Risk | Accounts Receivable [Member] | Service [Member] | Customer One [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage		53.00%	18.00%	18.00%
Credit Concentration Risk | Accounts Receivable [Member] | Service [Member] | Customer Two [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage			13.00%
Other Countries [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage		65.00%
Allergan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
One time payment, royalty revenues	$ 11,000
Allergan [Member] | U.S [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
One time payment, royalty revenues	$ 11,000
Merck KGaA [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member] | Product Segment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage		100.00%	100.00%

Segments and Geographic Infor63

Segments and Geographic Information - Selected Information by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 11,790	$ 12,986	$ 13,956	$ 11,247	$ 20,930	$ 11,556	$ 11,610	$ 10,477	$ 49,979	$ 54,573	$ 38,287
Total assets	61,220				57,571				61,220	57,571
Total Long-lived assets	16,124				14,502				16,124	14,502
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues									10,464	19,955	7,677
Total assets	21,683				21,423				21,683	21,423
Total Long-lived assets	523				663				523	663
Switzerland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues									33,264	27,302	23,139
Total assets	1,366				4,673				1,366	4,673
Total Long-lived assets	535				369				535	369
Nottingham, UK Facility [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues									3,559	4,632	4,422
Total assets	38,129				31,288				38,129	31,288
Total Long-lived assets	15,064				13,468				15,064	13,468
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues									2,692	2,684	3,049
Total assets	42				187				42	187
Total Long-lived assets	$ 2				$ 2				2	2
International [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues									$ 39,515	$ 34,618	$ 30,610

Segments and Geographic Infor64

Segments and Geographic Information - Schedule of Other Information by Segment (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues
Product revenues									$ 32,688	$ 27,211	$ 22,891
Service revenues									17,291	13,065	11,651
Royalties										14,297	3,745
Total revenues	$ 11,790	$ 12,986	$ 13,956	$ 11,247	$ 20,930	$ 11,556	$ 11,610	$ 10,477	49,979	54,573	38,287
Cost of product revenues									19,013	15,595	13,053
Cost of service revenues									9,948	8,698	8,361
Total cost of revenues									28,961	24,293	21,414
Gross profit	4,754	5,267	6,306	4,691	15,159	5,851	5,143	4,127	21,018	30,280	16,873
Total operating expenses	$ 5,271	$ 6,802	$ 6,662	$ 6,146	$ 6,042	$ 5,674	$ 7,420	$ 5,865	24,881	25,001	18,746
Total non-operating income									1,617	763	382
(Loss) income before income taxes									(2,246)	6,042	(1,491)
Product [Member]
Revenues
Product revenues									32,688	27,211	22,891
Royalties										14,297	3,745
Total revenues									32,688	41,508	26,636
Cost of product revenues									19,013	15,595	13,053
Total cost of revenues									19,013	15,595	13,053
Gross profit									13,675	25,913	13,583
Service [Member]
Revenues
Service revenues									17,291	13,065	11,651
Total revenues									17,291	13,065	11,651
Cost of service revenues									9,948	8,698	8,361
Total cost of revenues									9,948	8,698	8,361
Gross profit									$ 7,343	$ 4,367	$ 3,290

Segments and Geographic Infor65

Segments and Geographic Information - Schedule of Revenue by Customer (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Entity Wide Revenue Major Customer [Line Items]
Total revenues	100.00%	100.00%	100.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Merck KGaA [Member]
Entity Wide Revenue Major Customer [Line Items]
Total revenues	100.00%	66.00%	86.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Allergan [Member]
Entity Wide Revenue Major Customer [Line Items]
Total revenues		34.00%	14.00%

Quarterly Financial Informati66

Quarterly Financial Information (Unaudited) - Summary of Selected Quarterly Data (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 11,790	$ 12,986	$ 13,956	$ 11,247	$ 20,930	$ 11,556	$ 11,610	$ 10,477	$ 49,979	$ 54,573	$ 38,287
Gross profit	4,754	5,267	6,306	4,691	15,159	5,851	5,143	4,127	21,018	30,280	16,873
Operating expenses	5,271	6,802	6,662	6,146	6,042	5,674	7,420	5,865	24,881	25,001	18,746
(Loss) income from operations	(517)	(1,535)	(356)	(1,455)	9,117	177	(2,277)	(1,738)	(3,863)	5,279	(1,873)
Net (loss) income	$ 1,167	$ (1,410)	$ (376)	$ (1,441)	$ 9,614	$ 248	$ (2,268)	$ (1,643)	$ (2,060)	$ 5,951	$ (1,496)
(Loss) income per common share:
Basic	$ 0.11	$ (0.13)	$ 0.01	$ (0.13)	$ 0.89	$ 0.02	$ (0.21)	$ (0.15)	$ (0.15)	$ 0.55	$ (0.14)
Diluted	$ 0.11	$ (0.13)	$ (0.03)	$ (0.13)	$ 0.88	$ 0.02	$ (0.21)	$ (0.15)	$ (0.15)	$ 0.55	$ (0.14)

Quarterly Financial Informati67

Quarterly Financial Information (Unaudited) - Additional Information (Detail) $ in Millions	3 Months Ended
	Dec. 31, 2016USD ($)
Quarterly Financial Information Disclosure [Abstract]
Non-refundable royalty received	$ 11

Restructuring Charges - Additio

Restructuring Charges - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017USD ($)
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 777,000
Additional restructuring charges	0
Restructuring	249,000
Restructuring payments expected to be paid in 2018 or beyond	100,000
Stock-based Compensation Expense [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring charges	17,000
Fixed Asset Impairments [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring charges	14,000
Prepaid Amortization Associated With Manufacturing Contracts [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 37,500

Restructuring Charges - Summary

Restructuring Charges - Summary of Components of Restructuring Activity (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Restructuring Cost And Reserve [Line Items]
Expense incurred during the year ended December 31, 2017	$ 708
Amounts paid during the year ended December 31, 2017	(353)
Amounts accrued at December 31, 2017	355
Employee Severance, Benefits and Related Costs [Member]
Restructuring Cost And Reserve [Line Items]
Expense incurred during the year ended December 31, 2017	412
Amounts paid during the year ended December 31, 2017	(340)
Amounts accrued at December 31, 2017	72
Obligations under Manufacturing and Development Contracts [Member]
Restructuring Cost And Reserve [Line Items]
Expense incurred during the year ended December 31, 2017	296
Amounts paid during the year ended December 31, 2017	(13)
Amounts accrued at December 31, 2017	$ 283